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Abstract 
In this study, an efficient methodology for the preparation of carbohydrate-RNA 
conjugates was established, which involved the use of 3,4~diethoxy-3-cyclobutene-l,2-
dione (diethyl squarate) as the linking reagent. First, a glycan moiety containing an 
amino group reacted with diethyl squarate to form an activated glycan, which further 
reacted with an amino modified oligoribonucleotide to form a glycoconjugate under 
slightly basic conditions. The effect of glycosylation on the stability of RNA molecules 
was evaluated on two glycoconjugates, monomannosyl UlO-mer and dimannosyl UlO-mer. 
In the synthesis of aromatic fluorescent ribosides, perbenzylated ribofuranosyl pyrene 
and phenanthrene were synthesized from perbenzylated ribolactone. Deprotection of 
benzyl-protected ribofuranosyl phenanthrene and pyrene by boron tribromide gave 
ribofuranosyl phenanthrene and ribopyranosyl pyrene, respectively. UV/vis and 
fluorescent properties of the ribosides were characterized. 
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Chapter 1 - Introduction 
1.1 Introduction of nucleic acids 
In 1869, Miescher isolated a phosphorus containing substance from the pus cell nuclei, 
which he named "nuclein". In fact, this nuclein was really a nucleoprotein. In 1889, 
Altman was able to obtain the first protein-free material which he gave the name nucleic 
acid. In the late 19th century, the pyrimidine and purine bases were isolated and 
characterized by Kossel and Fischer. The double helix structure of DNA was discovered 
by Watson, Crick, Franklin, and Wilkins in 1953.1-3 The discovery of the DNA double 
helical structure directed enormous development in nucleic acid research. 
Nucleic acids may be subdivided into ribonucleic acid (RNA) and deoxyribonucleic acid 
(DNA). The basic building blocks of nucleic acids are nucleotides 1 (Figure 1.1), which 
are the phosphate esters of nucleosides 2 (Figure 1.1). Each nucleotide consists of a 
nitrogen heterocyclic base, a pentose sugar, and a phosphate backbone. Base residues 
include pyrimidines and purines. The pyrimidine bases are thymine 3, cytosine 4, and 
uracil 5; the purine bases are adenine 6 and guanine 7. In nucleosides, the purine or 
pyrimidine bases are joined from N-l of pyrimidine or the N-9 of the purines to the 
anomeric carbon of a pentose sugar. In RNA 2b (Figure 1.1), the pentose sugar is D-
ribose which is a five-membered furanose ring; in DNA 2a (Figure 1.1), the pentose 
sugar is 2-deoxy-D-ribose. In the DNA series, the four bases consist of guanine, cytosine, 
adenine, and thymine; while in RNA uracil replaces thymine. 
1.2 Introduction of small interference RNA (siRNA) 
In recent years, nucleic acids have found a wide range of therapeutic applications such as 
gene therapy, antisense oligonucleotides, aptamers, and RNA interference.4, 5 Of 
paticular interest, the potential use of siRNAs has attracted great attentions as a novel 
approach for specific gene silencing. 
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Figure 1.1: Basic structures of nucleic acids 
siRNAs are double stranded RNA (dsRNA) molecules which usually contain 21 to 23 
nucleotides in length including 2-nucleotide overhangs at the 3' -termini of each 
strand. When introduced to a cell, siRNAs can silence gene expression through the RNA 
interference (RNAi) pathway. RNAi is a naturally occurring biological process in which 
dsRNAs direct the degradation of complementary target RNAs. In 1998 Fire and Mello 
demonstrated that dsRNA was able to inhibit gene expression in C. elegans.6 Such 
dsRNA-mediated gene silencing was later identified in Drosophila, zebrafish, and 
13 
mammals. RNAi pathways are guided by small RNAs that include siRNAs and 
microRNAs (miRNAs)7, 8 as shown in Figure 1.2. First, long dsRNAs or precursor 
miRNAs (pre-miRNAs) are processed by the RNase III enzyme Dicer into siRNAs or 
miRNAs repectively. Then, the siRNAs or miRNAs are incorporated into RNA-inducing 
silencing complexes (RISe). The endonuclease Argonaute 2 (AG02) in the RISe 
mediates the cleavage of sense strand of siRNAs or unwinding of the miRNA duplex. 
The RISe complexes are activated while the single-stranded antisense strand is generated. 
The antisense strand of the activated RIse complexes acts as a guide sequence to target 
complementary messenger RNA (mRNA). Finally, the target mRNA is cleaved or 
degraded by the catalytic domain of AG02 in RISe, resulting in sequence specific 
inhibition of gene expression. 
Although dsRNAs can cause potent genetic interference, achieving RNAi in mammalian 
cells was initially unsuccessful because dsRNA induces a powerful interferon response. 
This response leads to the inhibition of all gene expression and rapid cell death.9 
Fortunately, Tuschl and colleagues discovered that introduction of synthetic siRNAs did 
not stimulate an interferon response but rather led to sequence-specific mRNA 
degradation in mammalian cells.1O These synthetic siRNAs, which are usually 21-23 
nucleotides in length, are long enough to induce RNAi, but small enough to avoid 
inducing interferon response. Further studies demonstrated that duplexes of 21-
nucleotide siRNAs with 2-nucleotide 3' overhangs were shown to be the most efficient 
triggers of RNAi-based mRNA degradation. ll These studies provided a very powerful 
tool for researchers working in mammalian systems to selectively and rapidly suppress 
genes of interest using such synthetic siRNAs. 
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siRNAs participate in repeated cycles of degradation of specific mRNAs, so protein 
production can be efficiently inhibited. Theoretically, siRNAs can be used to cure any 
disease that is caused by the expression of deleterious genes. The major advantage of 
siRNA therapy is that it interferes with the synthesis of disease-causing proteins at an 
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early stage of gene expression. Therefore, siRNA is considered as a means of sequence-
specific therapeutics against a wide range of diseases. As such, several companies are 
focusing on the development of RNAi-based therapeutics. 12 
1.3 Challenges in siRNA development 
The success of gene silencing by synthetic siRNA in mammalian cells has led to high 
expectations for siRNA as an important tool in gene regulation for therapeutic 
development. However, the development of siRNA molecules as therapeutic agents is 
faced with a number of challenges, particularly their relatively poor in vivo stability, poor 
delivery efficiency, and potential off-target effects. 13 
1.3.1 Improvement of siRNA stability 
dsRNAs are quite stable in cell culture media. It was observed that dsRNAs are stable in 
5% fetal bovine serum for up to 72 h, while the single stranded (ssRNA) was 
completedly degraded as short as 30 s under the same condition. 14 However, the situation 
is more complex in vivo. dsRNAs are less stable in higher concentrations of serum. 13 
When dsRNAs were incubated in 50% mouse serum, degradation was observed after 24 
h.15 In order to improve the serum stability of siRNAs, a number of chemical 
modifications have been investigated. Many of these modifications were initially 
designed for antisense applications. The most important chemical modifications include 
backbone modifications like phosphorothioate linkages and ribose modifications. 
1.3.1.1 Phosphorothioate linkages 
In phosphorothioate linkages 9, one of the non-bridging oxygen atoms in the phosphate 
backbone 8 is replaced with a sulfur atom (Figure 1.3). It was reported that 
phosphorathioate modification did not significantly affect RNAi activities. 14 Although 
introduction of phosphorothioate linkages into duplex RNAs provides significant 
improvement in serum stability, it decreases hybridization affinity which is indicated by 
reduction in melting temperature (Tm) values compared with unmodified RNA duplex. 14 
16 
Another study found that the cytotoxicity was observed with phosphorathioate 
modification of siRNA in human keratinocyte cell line HacaT. 16 
1.3.1.2 Ribose modifications 
Many modifications to the ribose residues of RNAs were investigated in order to increase 
the enzymatic stability of siRNA as well as their hybridization affinity. Among these, 2'-
O-methyl ribonucleotides 10, 2'-deoxy-2'-fluoro (2'-F) nucleotides 11, and locked 
nucleic acids (LNA) 12 (Figure 1.3) have been wen evaluated. 
1.3.1.2.1 2'-O-Methyl modification 
siRNA with 2'-O-methyl modification 10 showed resistance to fetal bovine serum and 
slightly increased hybridization affinity, with an increase of Tm by upto 1°C per 
modification. 14 Several siRNA sequences with 2' -O-methyl residues at different 
positions have been investigated for their effects on both the stability and silencing 
efficiency.17 It was shown that 2' -O-methyl modifications at certain positions in the 
siRNA duplex can increase stability in serum without significant loss of RNAi activity. 
siRNAs with two to four 2' -O-methyl modified nucleotides in either strand efficiently 
mediated RNAi acitivity. However, siRNA molecules with either one or both strands 
fully substituted by 2' -O-methyl residues were not able to induce RNAi activity in 
mammalian system. 17 
1.3.1.2.2 2'-F modification 
It has been reported that the introduction of 2' -F modification 11 increased the thermal 
stability of RNA duplexes. ls In addition, 2'-F modification has been shown to be well 
tolerated in siRNA applications. 19 When 2'-F modifications were introduced at the 3'-
termini or internal positions of RNA strands, the resulting siRNAs led to efficient 
inhibition of gene expression. 14 These findings suggest that partial substitution with 2'-
deoxy-2' -fluoro nucleotides is well accommodated in RNAi pathway. The idea of 2'-F 
modification provides another option for optimizing RNAi in mammalian cells. 
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1.3.1.2.3 LNA modification 
LNA-RNA duplexes that contain LNA nucleotides 12 at 3'-, 5'-, or both 3'- and 5'-
termini (Figure 1.3) were able to block gene expression. 14 In contrast, LNA-RNA 
duplexes that contained two LNA nucleotides within the central region were ineffective 
in gene silencing. 14 It was also observed that introduction of LNA nucleotides 
substantially increased T m values. Optimization of the numbers and position of LNA 
substitution may offer a useful strategy for RNAi applications. 
Unmodified RNA 
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Figure 1.3: Chemical modifications of RNA 
1.3.1.2.4 2'-O-Methyll0 in combination with 2'-F 11 or LNA 12 modifications 
Recently several groups have demonstrated the advantages of using 2'-O-methyl in 
combination with other modifications in siRNAs. Soutschek et al. reported the in vivo 
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silencing of apolipoprotein B (ApoB) using chemically modified siRNAs containing 2'-
O-methyl modification combined with phosphorothioates. The siRNA that had two 
modified nucleosides (2' -O-methyl combined with phosphorothioate) at the 3' -end of 
antisense strand and a cholesterol moiety conjugated to 3' -end of sense strand induced 
potent RNAi activity.20 
Combination of2'-O-methyl with 2'-F modifications has been examined by Allerson et al. 
21 In their study, a fully 2'-modified siRNA that consists of alternating 2'-O-methyl and 
2'-F modifications in both strands displayed an increase of in vitro potency as well as 
enzymatic and thermal stabilities.21 Therefore, alternating 2'-F/2'-O-methyl 
modifications may prove to be a useful strategy in designing functionally active and 
stable siRNAs. 
1.3.1.3 Chemical modifications of the termini and conjugate groups 
A 5' -phosphate on the antisense strand of an siRNA duplex is required for siRNA target 
cleavage in mammalian cells.22 siRNAs with a 5'- free hydroxyl on their antisense 
strands can mediate RNAi function because it can be phosphorylated by cellular kinases. 
It was found that siRNA in which 5' -hydroxyl termini of the antisense strand was 
blocked as 5' -methoxy failed to induce RNAi acitivity.22 In contrast, 5' -modification of 
the sense strand had no effect on silencing activity.17 Blocking 3' -hydroxyl of the 
antisense strand by a C6-amino modifier group did not affect on efficiency or specificity 
ofRNAi in flies or mammals.22 
Certain terminal conjugates in the sense strand of siRNAs have been reported to improve 
RNAi activity. Soutschek et al. reported in vivo silencing of ApoB mRNA by 
cholesterol-conjugated siRNAs which contain phosphorothioate backbone modification 9, 
2'-O-methyl modification 10, and a cholesterol moiety.20 In their study, both sense and 
antisense strands of siRNAs were modified by phosphorothioate backbone and the 
antisense strand contains two 2' -O-methyl nucleotides at the 3' -end. Cholesterol-siRNAs 
(Chol-siRNAs) were synthesized by linkage of cholesterol to the 3' -end of the sense 
strand via a pyrrolidine linker. It was found that Chol-siRNAs was significantly more 
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stable than unconjugated siRNAs in human serum without significant loss of the gene-
silencing activity in cell culture. Lorenz et al. synthesized the lipid conjugates of siRNAs 
by covalently linking lipid moieties to the 5' -ends of the siRNA sense strand using 
phosphoramidite chemistry.23 General structure oflipid-containing phosphoramidite 13 is 
illustrated in Figure 1.4. The resulting lipid-siRNAs improved in vitro cellular uptake 
and silencing efficiency in liver cells. 
Lipid) I 'vO, /O~ 
-'\'In ~ eN iNy 
13 
Figure 1.4: Lipid-containing phosphoramidite 
1.3.1.4 Glycosylation 
Naturally glycosylated DNAs in T-even bacteriophages have been discovered to enhance 
the resistance of these DNA molecules to deoxyribonucleases.24 It was found that 
glucose was present as an O-glycoside of the 5-hydroxymethyl substituent on the 
pyrimidine residue of DNA of T2, T4, T6 bacteriophages. Although their biological 
roles have not yet been fully elucidated, strong evidences show that the glycosylation of 
DNA protects T-even phages DNA from degradation by deoxyribonucleases. However, 
the effect of glycosylation on the stability of RNA has not been investigated yet. 
1.3.2 Improvement of siRNA delivery efficiency 
siRNAs are relatively large molecules with multiple negative charges. Because of the 
electrostatic repulsion between these negative charges and the negative charges on cell 
membranes, their cellular uptake is inefficient. Several approaches have been 
investigated in order to develop an appropriate delivery tool for siRNA therapies. 
1.3.2.1 Lipids 
Development of potential siRNA therapeutics against liver cell-specific diseases such as 
hepatitis C is hampered because human liver cells show poor uptake of these nucleic 
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acids. Since the liver is involved in lipid and steroid metabolism, several studies 
employed lipids to assist siRNA delivery via a receptor mediated mechanism or by an 
increased membrane permeability of the negatively charged RNA. A series of lipid-
modified siRNAs were synthesized by Hadwiger and co-workers in order to investigate 
the silencing potency of reporter gene expression.23 In their studies, the lipid moieties 
were covalently linked to the 5' -ends of the RNAs using phosphoramidite chemistry. It 
was found that siRNAs with a modified sense strand inhibit gene expression to a higher 
extent than siRNAs with a modified antisense strand or both strands modified. 
Unmodified siRNAs did not affect gene expression under the same conditions. 
1.3.2.2 Cholesterol 
In order to improve the delivery of siRNA into liver cells without transfection agents, a 
series of lipophilic siRNAs conjugated with derivatives of cholesterol were synthesized. 
Results by Soutschek and co-workers demonstrated that cholesterol conjugation may be 
able to address the siRNA delivery problem.20 The cholesterol-siRNA conjugates (Chol-
siRNA) were synthesized by incorporation of cholesterol to the 3' -end of the sense strand 
of an siRNA molecule via a pyrrolidine linker. The silencing effect on an ApoB gene by 
cholesterol- modified siRNAs was investigated. Chol-ApoB-siRNA, but not 
unconjugated ApoB-siRNA, resulted in vivo silencing of ApoB mRNA in liver and 
Jejunum. 
1.3.2.3 Liposomes 
Although neutral liposomes have been successfully used to deliver siRNA in ViVO,25 
cationic liposomes are more commonly used for siRNA delivery. Cationic liposomes are 
termed as "stable nucleic acid lipid particles" (SNALPs).26 In this approach, the 
negatively charged siRNA molecules interact electrostatically with cationic liposomes to 
form complexes that are able to be transferred into the cells (Figure 1.5). 
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Figure 1.5: siRNA delivery by cationic liposomes 
Torchilin and colleagues27 successfully delivered siRNA into lung tumor cells using 
siRNA encapsulated in liposomes bearing arginine octamer (R8) molecules attached to 
their surface. R8 belongs to a group of cell-penetrating peptides (CPP), which are 
positively charged and can enter cells more readily. In their studies, siRNA-loaded R8 
liposomes showed very high transfection efficiency in lung tumor cells and high stability 
III serum. 
In another study by Zimmermann et a!., the disease target ApoB in non-human primates 
was successfully silenced by systemic delivery of siRNAs in a liposomal formulation.28 
In their studies, the ApoB-specific siRNAs were encapsulated in stable SNALP and 
administered by intravenous injection to cynomolgus monkeys. The results suggest that 
delivery of siRNAs for targeting specific genes in higher species is possible, therefore 
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RNAi may represent a new strategy for reducing LDL-cholesterol levels in clinical 
settings. 
1.3.2.4 Peptides 
Peptide-based gene delivery system has been under investigation for nucleic acid 
delivery for over ten years.29-32 Divita et al. investigated MPG-mediated siRNA 
delivery.33 MPG, a short peptide vector (27 amino acid residues), contains a hydrophobic 
domain derived from the fusion sequence of HIV gp41 and a hydrophilic domain derived 
from the nuclear localisation sequence of SV40 large T-antigen.32 MPG forms stable 
non-covalent complexes with nucleic acids by electrostatic interactions. Results32 showed 
that MPG promotes the delivery of siRNA into mammalian cells in less than 1 h with 
efficiency of over 90%. In the absence of MPG, siRNA was taken up by at a very low 
level. 
1.3.2.5 Antibodies 
Lieberman and colleagues recently reported the development of antibody-protamine 
fusion proteins as vehicles for receptor-directed delivery of siRNA.34 They combined the 
nucleic acid-binding properties of the small basic protein protamine with the specific 
ligand-recognition properties of antibodies to achieve cell-type-specific siRNA delivery 
both in vitro and in vivo. The fusion protein (F105-P) was designed with the protamine 
coding sequence linked to the C terminus of the Fab fragment of an HIV -1 envelope 
antibody. siRNA binds to fusion protein non-covalently. With the assistance of 
protamine-antibody fusion proteins, the siRNA was successfully delivered to HIV-
infected cells and induced efficient gene silencing. Additionally, F105-P-complexed 
siRNA only targeted the cells expressing HIV-l envelope, but not normal tissues. These 
results demonstrate that silencing using antibody-mediated delivery is both efficient and 
specific. 
1.3.2.6 Viral vectors 
Viral vectors are highly efficient delivery systems for nucleic acids. Different viral 
vectors encoding short hairpin RNA (shRNA) including lentiviruses,35 adenoviruses,36 
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and adeno-associated viral vector37 are being developed for delivery of siRNA. However, 
their clinical application is hindered by induction of adverse immune responses and 
inadvertent changes in gene expression following random integration into the host 
genome. 
1.3 .2.7 Glycotargeting to improve cellular delivery efficiency of siRNAs 
Apart from the above approaches, utilizing interactions on cell surfaces is another 
strategy in the design of efficient delivery platform in siRNA therapies. Using 
carbohydrate ligands to target protein receptors by the mechanism of receptor-mediated 
endocytosis is called glycotargeting.38 The idea of using carbohydrates to create a 
targeted drug delivery system was first demonstrated in 1971.39 Lectins, which are 
proteins existing on cell surfaces, recognize and bind to carbohydrates with high 
specificity. Utilizing lectin-glycan interactions to mediate cell targeting and cellular 
uptake of molecules has been under intense investigation during the past two decades.4o 
A nucleic acid delivery system that exploits the interactions between glycans and lectins 
is a relatively recent technique first implemented by Wu and WU.41 Carbohydrate 
moieties have been proved to improve cellular delivery efficiency of deoxyribonucleic 
acid. Following this pioneer study, many different variations using lectin-ligand 
interactions in nucleic acid delivery have been developed. The developments in nucleic 
acid glycosylation are summarized in comprehensive review articles by Yan42 and 
Oretskaya43 respectively. 
Nucleic acid glycosylation can be prepared as non-covalently associated carbohydrate-
nucleic acid complexes and covalently-linked carbohydrate-nucleic acid conjugates. In 
the first approach, the non-covalent nucleic acid complexes (glycoplexes) can be formed 
through ionic interactions, protein-ligand interactions,44 nucleic acid-intercalator 
interactions,45 and nucleic acid-polysaccharide interactions.46 In the second approach, 
carbohydrates and nucleic acids are linked by covalent bonds. So far, a number of 
systems have been investigated in the preparation of carbohydrate-nucleic acid 
conjugates including: 
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• Coupling of sugar phosphoramidites with oligonucleotides;47 
• Enzymatic elaboration of carbohydrate moiety of a glycosylated 
oligonucleotide; 48 
• Derivatization from the nucleoside base residues;49 
• Diazocoupling;50 
• Oximation;51 
• Reductive amination;52 
Compared to glycoplexes, the conjugates from the second approach tend to be more 
homogeneous and easily characterized. However, the difficulties in the preparation of 
covalent conjugates and steric effects caused by some covalent linkages on binding 
properties make the second approach quite challenging. 
1.4 Chemical synthesis of oligorihonu.cleotide sequences 
1.4.1 Overview of chemical synthesis of oligonucleotides 
Since the discovery of the double helical structure of DNA in 1953,1-3 tremendous efforts 
have been made in the chemical synthesis of oligonucleotides. The essence of 
oligonucleotide synthesis is the fonnation of intemucleotide 3' --75' phosphodiester 
linkages. However, this reaction is complicated by the presence of two or three hydroxyl 
functions in nucleosides and reactive functional groups in the base residues. It is very 
important to protect these groups appropriately to ensure fonnation of correct 
intemucleotide linkages during the coupling reaction and subsequent purification. 
The first chemical synthesis of an oligonucleotide with a natural 3'--75' intemucleotide 
linkage was reported by Michelson and Todd.53 Over the past fifty years, several 
methods for the syntheis of oligonucleotides have been established. Based on the ways of 
making the intemucleotide linkage, these methods are grouped into the phosphodiester,54 
phosphotriester,53 
approaches. 57 
phosphite triester,55 phosphoramidite56 and H -phosphonate 
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1.4.2 Phosphoramidite approach 
Among the methods described above, phosphoramidite chemistry is the most widely 
used approach in oligonucleotide synthesis on solid phase since its invention. In this 
approach, first introduced by Beaucage and Caruthers,56 monofunctional nucleoside 
phosphoramidites are used as a new class phosphorylating reagent. In their original 
studies (Scheme 1.1), 5' -O-dimethoxytrityl (DMTr) 20 protected deoxyribonucleoside 
was first allowed to react with chloro-N,N-(dimethylamino)-methoxyphosphine 
(R1=R2=Me in IS) m the presence of N,N-diisopropylethylamnine to give the 
corresponding nucleoside phosphoramidite 16. Upon activation, the phosphoramidite 16 
coupled rapidly with a second nucleoside 17 bearing a free 5' -hydroxyl function to afford 
a phosphite triester 18. After oxidiation by iodine, the stable phosphate triester 19 was 
produced. 
IH-Tertrazole was chosen as a suitable activating agent in the phosphoramidite approach. 
Since 3'-O-(methoxy-N,N-dimethyl)phosphoramidites (RI=R2=Me in 16, Scheme 1.1) 
were found to be unstable in solution, several stable phosphoramidite derivatives have 
been developed. Among them, 3' -O-(2-cyanoethyl-N,N-diisopropyl)phosphoramidites 
(R1=CH2CH2CN, R2=Me2CH in 16, Scheme 1.1) were proved to be stable in solution. 
The cyanoethyl groups for protecting intemucleotide linkages are readily removable 
under the conditions required for the removal of the nucleobase protecting groups, i.e. 
incubation in concentrated aqueous ammonium hydroxide.58 Since then, 2-cyanoethyl-
N,N-diisopropylphosphoramidites (R1=CH2CH2CN, R2=Me2CH in 16, Scheme 1.1) have 
been used widely in phosphoramidite-based solid phase oligonucleotide synthesis. 
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Scheme 1.1: The original phosphoramidite chemistry. Reagent and conditions: i, (i-
Pr)2NEt, CHCh, r.t.; ii, IH-tetrazole, CH3CN; iii, iodine. 
1.4.3 Solid phase oligonucleotide synthesis 
Solid phase oligonucleotide synthesis involves the addition of one nucleotide residue or a 
blockmer at a time to a protected nucleoside or oligonucleotide on a solid support. 
Controlled-pore glass (CPGi9 and higly crosslinked polystyrene6o are both robust 
materials and are used as choices of solid support. CPG has proved to be generally useful 
solid supports and have been used successfully in the automated solid phase 
oligonucleotide synthesis since 1981.59 The terminal nucleoside is commonly attached to 
solid supports via a succinoyl group 22 as in Figure 1.6. 
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Figure 1.6: Succinoyl group attached to CPG 
Solid phase oligonucleotide synthesis via the phosphoramidite approach has been widely 
used for synthesis of DNA and RNA sequences since 1980s because of (i) commercial 
availability of automatic synthesizers, phosphoramidite building blocks and reagents; and 
(ii) efficiency in the synthesis of oligonucleotides. In this approach, the various steps 
involved in each cycle of synthesis are illustrated in Scheme 1.2. Each cycle starts with 
the detritylation step which is the removal of the DMTr group to free the 51-hydroxyl for 
the coupling reaction. Coupling is achieved by the addition of an activator such as IH-
tetrazole, 5-( ethylthio )-lH-tetrazole (ETT), and 5-(benzylthio )-lH-tetrazole (BTT). Then 
the capping step follows, which terminates any unreacted chains with a free 5'-OH by 
acetylation using acetic anhydride and N-methylimidazole. Subsequent oxidation step 
converts the unstable phosphite triester linkages to the stable phosphate triester linkages. 
Once the chain is assembled, the oligonucleotide is then cleaved from the solid support 
by treatment with aqueous ammonia. Meanwhile, all the protecting groups are also 
cleaved, including the cyanoethyl protecting groups for the intemucleotide linkages and 
the acyl protecting groups for the bases. 
1.5 2'-Hydroxyl protecting groups in the synthesis of oligo ribonucleotide sequences 
There has been increased interest in the chemical synthesis of oligoribonucleotides since 
the discovery of the siRNA technology. However, the chemical synthesis of 
oligoribonucleotides lagged a long way behind the well-established 
oligodeoxyribonucleotide synthesis. Compared to the synthesis of DNA, preparation of 
RNA sequence is more complex due to the presence of 2'-hydroxyl function in RNA 
which causes undesirable side reactions. Protection of 2' -hydroxyl function lowers 
coupling yields in chain assembly because of steric hindrance of protecting groups. 
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Besides the inefficiency in coupling reaction, the instability of RNA in both acidic and 
basic media is another hurdle in RNA chemistry.61 
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Scheme 1.2: Solid phase synthesis of oligonucleotide usmg the phosphoramidite 
chemistry 
It is therefore obvious that the most crucial decision to be taken in the chemical synthesis 
of RNA sequences is the choice of2'-OH protecting groups. This protecting group must 
remain completely intact throughout the synthesis and must then be removed in the final 
deblocking step without causing any cleavage or migration of intemucleotide chain. 
These are very demanding requirements, since the intemucleotide linkage of RNA easily 
undergoes both base-catalyzed hydrolysis and acid-catalyzed hydrolysis and migration.62 
It is possible to separate synthetic oligonucleotide from the cleavage products by either 
HPLC or polyacrylamide gel electrophoresis (PAGE). However, it is virtually impossible 
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, to separate the oligonucleotide from the impurities containg 2'-5' intemucleotide linkage 
resulted from migration. If an acid labile group is used to protect the 2'-hydroxyl 
function in oligonucleotide synthesis, it must be removable under very mild conditions to 
avoid degradation and migration of the intemucleotide linkages. 
Based on the deblocking conditions, the 2' -OH protecting groups can be grouped into 
four major categories: protecting groups removable under nearly neutral conditions, base 
labile protecting groups, acid labile protecting groups, and protected protecting groups 
(which are usually removed in two steps). 
1.5.1 Protecting groups removable under nearly neutral conditions 
1.5.1.1 Benzyl 
The benzyl protecting group is removable by catalytic hydrogenolysis.63 The major 
drawbacks of this protecting group are incomplete 2' -deblocking and hydrogenation of 
the 5,6-double bonds of cytosine and uracil residues. This protecting group has very 
rarely been used in oligoribonucleotide synthesis. 
1.5.1.22-Nitrobenzyl 
The 2-nitrobenzyl group 29 (Figure 1.7) is removable photolytically above 280 nm under 
acidic conditions.64 However, phosphoramidite monomers derived from 2' -O-nitrobenzyl 
group ribonucleosides need extended coupling time due to steric hindrance by the bulky 
2' -protecting group. A more serious problem is the formation of photoadducts under the 
conditions for the removal of nitrobenzyl. 
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Figure 1.7: Protecting groups removable under nearly neutral conditions 
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1.5.1.3 tert-Butyldimethylsilyl (TBDMS) 
TBDMS group65 30 (Figure 1.7) is the most widely used 2'-OH protecting group. 
TBDMS is moderately stable to the acidic conditions used for deblocking of the 5'-0-
DMTr group and is removable by treatment with tetrabutylammonium fluoride 
(TBAF).66 The problems associated with TBDMS group are rather long coupling times 
(ca. 10 min), lack of regio-selectivity in its introduction, and base-catalyzed migration67 
in Scheme 1.3(a). Despite the ease of migration, relatively pure monomeric 
phosphoramidites (R=TBDMS in 33, Figure 1.8) with a very small quantity of isomeric 
3'-0-TBDMS-2'-phosphoramidites are commercially available and have served well in 
the solid phase RNA synthesis. 
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Scheme 1.3: Base-catalyzed migration ofTBDMS protected ribonucleotides 
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Figure 1.8: RNA phosphoramidite building blocks 
1.5.2 Base labile protecting groups 
Acyl groups are the most common base-labile protecting groups for 2' -hydroxy functions. 
The use of base-labile protecting group is very limited because acyl groups very readily 
undergo base-catalyzed migration68 as shown in Scheme 1.3(b). 
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1.5.3 Acid labile protecting groups 
The use of acid-labile 2' -protecting groups has the considerable advantage of being 
stable under the basic conditions which are used to remove the protecting groups from 
the nucleoside residues and the intemucleotide linkages, as well as to cleave the fully-
assembled RNA sequences from solid support. 
DMTr 20 (Scheme 1.1) group has been used for the temporary protection of 5'-hydroxy 
functions in most solid phase synthesis of oligoribonucleotides. Obviously, if the acid-
labile groups are to be used to protect 2' -hydroxy functions, they must be compatible 
with the 5' -hydroxy DMTr protecting groups and be readily removable under the mildest 
possible conditions of acidic hydrolysis in the final deblocking step. Acetal protecting 
groups are most commonly used acid-labile 2' -protecting group with the advantages in 
that they can be introduced regiospecifically to the 2' -hydroxy function of a 
ribonucleoside derivative and, once in place, they do not migrate. 
1.5.3.1 Thp and Mthp 
Tetrahydropyran-2-yl (Thp) group 34 (Figure 1.9) was the first acid-labile 2' -protecting 
group investigated.69 The cleavage and migration of the 2'-O-Thp uri dine dinucleotide 
were found to occur in a negligible extent under the deprotection conditions (PH 2.0). 
Later, the Thp group was abandoned due to its chirality. Soon after, the achiral 4-
methoxytetrahydropyran-4-yl (Mthp) protecting group 35 (Figure 1.9) was developed.7o 
The Mthp group is more than twice as labile as the Thp group at pH 2.0. However, both 
Thp and Mthp groups can not withstand repeated exposure to the relatively drastic acidid 
conditions used for detritylation in oligonuceotide synthesis on a solid support. A series 
of studies were followed in order to pursue suitable 2' -hydroxyl protecting groups which 
are compatible to the use of 5'-DMTr group and removable under conditions similar to 
those required for the cleavage of the Mthp group. 
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Figure 1.9: Acid labile protecting groups: Thp and Mthp 
1.5.3.2 Acetals with a piperidine moiety 
In the pioneer studies on the design of protection groups for 2'-hydroxyl function in 
chemical synthesis of oligonucleotides, Reese and co-workers71 found that the rate of 
acid-catalyzed hydrolysis of acetal systems (Scheme 1.4) is very sensitive to the 
inductive effect of the atom or group X. The sulfone acetal (X=S02 in 36) is less acid 
labile than the Mthp (X=O in 36) group; in contrast, the sulfur-containing protecting 
group (X=S in 36) is more acid labile than Mthp group. 
MeOR MeoR H+ MeoR 
N /N, X I 
Ar Ar H 36 
37 38 
Scheme 1.4: Acid-catalyzed hydrolysis of acetal systems 
In a typical acetal system, the rate of hydrolysis is pH dependant and increases 
logarithmically with decreasing pH which were observed in the unblocking of Thp and 
Mthp groupS.72 Designing an acetal system which has virtually pH independent 
hydrolysis properties in the pH range of 0-2.5 led to the discovery of the acetal systems 
with piperidine moiety. 
In a l-arylpiperidin-4-one acetal system, the weakly basic tertiary amine function (pKa 
ca. 2) has this desired property. It would be largely protonated 38 in the presence of 
excess of trichloroacetic acid (pKa 0.66) during the 'detritylation' step and largely 
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unprotonated 37 (Ar = aryl, Scheme 1.4) during the final deblocking step (above pH 3). 
The difference in the inductive effect of the protonated N-aryl group 38 and the 
unprotonated N-aryl group 37 would result in the rate hydrolysis of the acetal being 
several orders of magnitude faster than that of the acetal in its conjugate acid. It can be 
concluded that the rate of hydrolysis of acetal system should be pH independent within a 
specific pH range from somewhere below to somewhere above the pKa of the tertiary 
amino function. Carefully choosing aryl constituent would ensure that rate of acetal 
hydrolysis is pH independent in the desired range of pH. 
1.5.3.2.1 Ctmp 
1-(2-Chloro-4-tolyl)-4-methoxypiperidin-4-yl (Ctmp) 39 (Figure 1.10) is the first 
piperidine acetal system used for the protection of 2' -hydroxyls in oligoribonucleotide 
synthesis.72 The rate of acetal hydrolysis hardly changes between pH 0.5-2.0. In addition, 
this l-arylpiperidin-4-one acetal system has an acid lability similar to that of Mthp group 
35 under mild acidic conditions (pH 2.0-2.5, room temperature). These findings proved 
that Ctmp group 39 meets the requirements of 2'-hydroxy protecting groups, i.e. stable 
under the acidic conditions required for the detritylation step and removable under mild 
acid conditions. 
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Figure 1.10: Acetals with a piperidine moiety 
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1.5.3.2.2 Fpmp 
Although Ctmp 39 is an effective group for protecting 2'-hydroxyl function in RNA 
synthesis, the original development of the Ctmp 39 was limited by the difficulty in the 
preparation of the enol ether reagent 45a (Scheme 1.5) required for the introduction of 
the Ctmp protecting group. Subsequent studies on the synthesis of the enol ether reagents 
45 led to the development of 1-(2-fluorophenyl)-4-methoxypiperidin-4-yl (Fpmp) 40 
(Figure 1.10).73 The enol ether reagents required for the introductions of Ctmp 39 and 
Fpmp 40 protecting groups can be prepared using the general method74 illustrated in 
Scheme I.5a and Scheme 1.5b, respectively. As a halogenated piperidinyl protecting 
group, the Fpmp has almost the same hydrolysis properties as Ctmp protecting group. 
Studies suggest that Fpmp is able to withstand the acidic conditions required for 
detritylation and it is readily removable at pH 3.0 without detectable migration or 
cleavage of the intemucleotide linkages.75 Fpmp has been used successfully in the 
preparation of the protected ribonucleoside building blocks in the solid phase synthesis. 
ROR OR 
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Scheme 1.5: Preparation of enol ether reagents. Reagents and conditions: i, (a) 
TsOH'H20, ROH, reflux, 1.5 h; (b) (RO)3CH, reflux, 30 min; ii, (i-PrhNEt, Et20·BF3, 
CH2Ch,0°C. 
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1.5.3.2.3 Cpep 
Althgouh there is no doubt that Fpmp 40 is suitable for the protection of 2' -hydroxy 
functions in the chemical synthesis of RNA sequences, it is evident that the 
intemucleotide linkages of certain RNA sequences readily undergo cleavage and 
migration under even very mild acidic conditions for unblocking Fpmp protecting group 
(pH 2.0-2.5). Therefore, it would be beneficial if 2' -protecting group is removed at or 
above pH 3.25.75 Ideally, a l-aryl-4-alkoxypiperidin-4-yl protecting group should be as 
stable as Fpmp group at pH 0.5 but more labile at pH 3.5 or higher. Among the fourteen 
piperidinyl protecting groups examined, the 1-( 4-chlorophenyl)-1-ethoxypiperidin-4-yl 
(Cpep) group 41 (Figure 1.10) had advantages over the others including Fpmp.75 
The Cpep protecting group has a better acid hydrolysis profile (Figure 1.11) than the 
Fpmp group.75 Compared with Fpmp, Cpep is more stable to acidic hydrolysis in the pH 
range of 0.5 to 2.0 but more than twice as labile at pH 3.75. Thus, rate of hydrolysis of 
Cpep at pH 3.75 is only 3.73 times slower than at pH 0.5. The half-life of hydrolysis of 
2'-O-Cpep-uridine is only 170 min versus 266 min for Fpmp at pH 3.75 and 30°C, so 
that it can be removed in approximately one-half of the time required for deblocking 
Fpmp under the same conditions. The half-life of hydrolysis of 2' -O-Cpep-uridine is 
almost pH independent in the range of pH 0.5-2.5. 
In addition, preparation of Cpep group precursor is straightforward.74 The enol ether 
precursor, 1-( 4-chlorophenyl)-4-ethoxy-l ,2, 5, 6-tetrahydropyridine (4Sa) can be prepared 
from 4-chloroaniline in two-steps in 90% overall yield (Scheme I.5a). 
The 2'-O-Cpep protected phosphoramidites (R=Cpep in 33) can be prepared in the 
traditional approach. Complete removal of the 2' -protecting groups at pH 4.4 and 35°C 
required ca. 7 and 4 h for r[(Up)J9U] protected at 2'-positions with Fpmp and Cpep, 
respectively. No migration or cleavage of intemucleotide linkages was observed in either 
case. From this study, the Cpep group showed very promising properties in protecting 2'-
hydroxy function in oligoribonucleotide synthesis. 
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Figure 1.11: Dependence of the half-lives of hydrolysis at 30°C of the 2' -O-Fpmp- and 
2' -O-Cpep-uridines on pH 
l.5.4 Protected protecting groups 
1.5.4.1 Nitrobenzyloxymethyl (NBOM) 
Nitrobenzyloxymethyl (NBOM) groups 46 were developed to relieve the steric crowding 
in the vicinity of the phosphoramidite function by incorporating a flexible arm into the 
structure at the 2_0H.76-78 In the 2-nitrobenzyloxymethyl (2-NBOM) 46a and 4-
nitrobenzyloxymethyl (4-NBOM) 46b groups, formaldehyde acetal linkers were used to 
connect the bulky 2-nitrobenzyl to 2' -0 position of ribonucleosides. Introduction of 2'-
O-NBOM group led to coupling yields of over 98% under DNA coupling conditions. 
The 2'-0-(2-NBOM) group could be removed by UV photolysis at pH 3.7;76 and the 2'-
0-(4-NBOM) group could be removed by treatment with TBAF.77 Recently, Beaucage et 
at. reported that the convertion of 4-nitro group to 4-amino group in 2' -0-( 4-NBOM) 
facilitated the cleavage of2'-0-acetal in 0.1 M AcOH.78 
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1.5.4.2 Bis(2-acetoxyethoxy)methyl (ACE) 
In the late 1990s, Scaringe et at. developed the 2'-O-ACE protecting group 48 (Scheme 
1.7) for the RNA synthesis via the phosphoramidite chemistry.79 In this approach, the 5'-
hydroxy is protected with a silyl ether group (SIL) 47 (Figure 1.12) instead of a DMTr 
group. These silyl ether protecting groups could be removed with fluoride ions under 
neutral conditions which are compatible with an acid labile 2' -hydroxyl protecting group. 
In the ACE chemistry, the 3' -hydroxyl is phosphitylated as the methoxy N,N-
diisopropylphosphoramidite 47 (Figure 1.12) because the cyanoethyl phosphoramidites 
are not compatible with fluoride reagents used for removal of 5' -O-SIL protecting group. 
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Figure 1.12: 5' -O-SIL-2' -O-ACE RNA phosphoramidite building blocks 
As a protected protecting group, removal.of ACE is achieved in two steps (Scheme 1.6). 
First, ACE 48 undergoes ester hydrolysis under basic conditions used for nucleoside base 
deprotection to result in 2' -O-bis(2-hydroxyethoxy)methyl orthoester 49 which is 10 
times more acid labile than ACE itself. Then the 2' -O-bis(2-hydroxyethoxy)methyl 
orthoester 49 is completely removed under mild acidic conditions (pH 3, 10 min, 55°C). 
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Scheme 1.6: Deprotection of2'-0-ACE group 
An advantage of this chemistry is that the ACE group proved to be stable in 
oligonucleotide synthesis, purification, and storage. However, the ACE strategy is not 
compatible with the conventional automated synthesizer. Substantial changes in synthetic 
cycle and reagents were required in order to incorporate the 5' -0-SIL-2' -O-ACE 
phosphoramidite building blocks 47 (Figure 1.12) in solid phase synthesis. Nevertheless, 
these phosphoramidite building blocks have been commercially available and widely 
used in custom synthesis of RNA sequences. 
1.5.4.3 [(Triisopropylsilyl)oxy]methyl (TOM) 
[(Triisopropylsilyl)oxy]methyl (TOM) group 50 (Scheme 1.7), a silyl-protected acetal, 
was first used to protect the 2'-hydroxy functions in Pitsch's Lab.so As a variant of 
TBDMS 30, the TOM group 50 is deprotected in a two step process: (i) attack of Si-atom 
by fluoride ions results in cleavage of Si-O bond 51; and (ii) addition of aqueous buffer 
solution results in fragmentation to free 2' -OH (Scheme 1.8). 
50 
2'-0-TOM 
Scheme 1.7: Deprotection of2'-0-TOM group 
2'-OH 
The TOM group has several advantages over TBDMS group. First, in contrast to 
TBDMS protecting group, TOM group does not migrate from the 2'-0 to the 3'-0 
position. Therefore very pure phosphoramidites (R=TOM in 33, Fugure 1.8) could be 
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prepared via this approach. Second, because of the minimal sterie demand of the TOM 
group, excellent coupling yields of 99.5% with coupling time of 60-150s are obtained 
with 2'-0-TOM phosphoramidites. Furthermore, good stability of the 2' -0-TOM group 
allows for a variety of nucleobase, sugar, and backbone modifications in the preparation 
of the RNA sequences. However, TOM-protected oligoribonucleotides can not be 
purified by HPLC because of the hydrophobic nature of the silyl group. 
1.5.4.4 2-(Trimethylsilyl)ethoxymethyl (SEM) 
In order to improve the regioselectivity of 2' -O-protection and the slow coupling reaction, 
Sekine et al. developed the 2-(trimethylsilyl)ethoxymethyl (SEM) protecting group 52 
(Figure 1.13) which could be removed by treatment with fluoride ion.81 The 
regioselective introduction of the SEM group into the 2' -position was achieved in 78-
84% yields. The corresponding 2' -O-SEM phosphoramidite building blocks were found 
to be more reactive than 2' -0-TBDMS protected amidites in the solid phase synthesis. 
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Figure 1.13: Protected protecting groups: ~EM, CEM, and TEM 
1.5.4.5 2-Cyanoethoxymethyl (CEM) 
2-Cyanoethoxymethyl (CEM) 53 (Figure 1.13) is readily removable by treatment with 1 
M TBAF/THF for several hours.82 This formaldehyde acetal type protecting group 
posesses relatively less steric hindrance toward the vicinal 3' -phosphoramidite, therefore 
high coupling efficiency could be achieved. CEM method allows RNA synthesis with 
high coupling yields and gives products of high purity. Homo- and mixed-base RNA 
oligomers up to 55 bases in length have been synthesized via CEM chemistry with 
coupling yields greater than 99% in 60-150 s. Regio-selective introduction of 2' -O-CEM 
is still under investigation and the yields of the corresponding amidites need to be 
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optimized. Nevertheless, after suitable optimization, CEM method may have the 
potential for the synthesis of long RNA sequences. 
1.5.4.6 2-(4-Tolylsulfonyl)ethoxymethyl (TEM) 
Very recently Chattopadhyaya et al. introduced the 2-( 4-tolylsulfonyl)ethoxymethyl 
(TEM) 54 (Figure 1.13) as a new 2'-OH protecting group for solid phase RNA synthesis 
using phosphoramidite chemistry.s3 As a 2'-OH protecting group with a formaldehyde 
acetal linker, TEM was developed based on the modulation of the CEM group. It was 
found that the TEM group can be removed with TBAF in 5 min at room temperature. 
The TEM chemistry allows for relatively fast coupling reactions (120 s) to give relatively 
high average coupling yield (97-99%). 
1.5.4. 7 4-(N-Dichloroacetyl-N-methylamino )benzyloxYlPethyl 
Recently Beaucage reported the use of 4-(N-dichloroacetyl-N-methylamino) 
benzyloxymethyl group 55 (Scheme 1.9) for 2' -hydroxyl protection in solid phase 
synthesis of RNA sequences via phosphoramidite chemistry.84 4-(N-Dichloroacetyl-N-
methyl amino )benzyloxymethyl 55 is also a protected protecting group. 4-(N-
Dichloroacetyl-N-methylamino )benzyl alcohol was used for the preparation of the 
corresponding phosphoramidite building blocks. RNA phosphoramidites protected with a 
4-(N-dichloroacetyl-N-methylamino )benzyloxymethyl group for 2' -O-protection allow 
rapid and efficient solid-phase RNA synthesis. It was reported that average coupling 
yields of 99% with 5-ethylthio-lH-tetrazole as an activator and 3 min coupling resulted 
in high quality products without purification, which is comparable to standard solid-
phase DNA synthesis. 
N-Dichloroacetyl groups were cleaved under aqueous ammonium treatment which was 
used for the cleavage of nucleobase and phosphate protecting groups (Scheme 1.8). 
Consequently, the resulting 2'-O-(4-MABOM)-protected RNA oligonucleotide 56 was 
released from the solid support. The 2'-O-(4-MABOM) group was completely removed 
by treatment with 0.1 M AcOH (pH 3.8) in the presence of N,N,N',N'-
41 
tetramethylethylenediamine at 90°C for 30 min without significant intemudeotidic chain 
cleavage and migration (Scheme 1.9). 
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Scheme 1.8: Deprotection of 4-(N-dichloroacetyl-N-methylamino )benzyloxymethyl 
group 
Although the 4-(N-dichloroacetyl-N-methylamino )benzyloxymethyl group 55 allows for 
highly efficient coupling and facile deprotection, methods for convenient preparation of 
the four RNA building blocks still need to be optimized. 
1.6 Objectives of this thesis 
The principal aim of this thesis is to use specific glycosylation of synthetic RNA 
sequences to improve their stability, allow for specific cell targeting, and enhance their 
cellular uptake by addressing the following objectives: 
I) To synthesize RNA sequences by solid phase phosphoramidite chemistry 
using Cpep to protect 2' -hydroxyls; 
2) To establish a conjugation chemistry for the preparation of carbohydrate-
RNA conjugates; 
3) To evaluate the effects of glycosylation on the stability of RNA molecules; 
4) To synthesize and evaluate pyrene- and phenanthrene-based fluorescent 
ribosides. 
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Chapter 2 - Results and Discussions 
2.1 General strategy 
In this study, we aimed to use specific glycosylation of synthetic siRNA sequences to 
improve stability, specificity, and cellular uptake. The general strategy to achieve 
carbohydrate-RNA conjugates involved using 3,4-diethoxy-3-cyclobutene-l,2-dione 
(diethyl squarate )85 57 as the linking reagent. We previously reported a method that 
allows for easy incorporation of carbohydrate moieties into oligodeoxynucleotides under 
mild conditions. 86 In this approach, a glycan moiety 58 containing an amino group reacts 
with diethyl squarate to form an activated glycan 59, which further reacts with an 
oligonucleotide 60 to form a glycoconjugate 61 under slightly basic conditions (Scheme 
2.1). 
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Scheme 2.1: Squarate linker in the synthesis of glycosylated oligodeoxyribonucleotides 
In the current project, the dendritic cell was chosen as the target cell type to evaluate the 
impact of carbohydrate-derivatization on the bioavailability and silencing efficiency of 
siRNA. Dendritic cells (Des) are potent antigen presenting cells and play important roles 
in the immune system. Lectins on dendritic cells are relatively well characterized.s7,88 
Since the target lectins express macrophage mannose receptors, mannosides were chosen 
as glycan moieties and designed to be covalently attached to synthetic RNA sequences 
via diethyl squarate linker 62. 
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2.2 Synthesis of squarate-activated monovalent mannosides 
Fully-protected 2' -chloroethyl mannoside 67 was prepared from mannose 63 via the 
trichloroacetimidate chemistry. 89 The subsequent substitution by sodium azide gave 
fully-protected 2' -azidoethyl mannoside 68 (Scheme 2.2). Deacetylation of 68 followed 
by catalytic hydrogenation afforded the fully deprotected 2' -aminoethyl mannoside 69 
(Scheme 2.2). Catalytic hydrogenation of fully-protected 2' -azidoethyl mannoside 68 in 
the presence of trifluoroacetic acid (TF A) gave the trifluoroacetate salt of funy-protected 
mannoside 70. In the reaction, TF A was added to avoid the acetyl migration. 
The trichloroacetimidate method89 is a widely applicable procedure for formation of 
glycosidic bonds. In this approach, the anomeric hydroxyl of a suitably protected 
saccharide is treated with trichloroacetonitrile under basic conditions to give a glycosyl 
trichloroacetimidate. The glycosylation step is then effected by a Lewis acid. The 
stereochemical outcome of trichloroacetimidate formation is subjected to both kinetic 
and thermodynamic control. The thermodynamically more stable a-trichloroacetimidate 
can be obtained using a strong base such as DBU. If glycosylation is carried out in 
nonpolar solvents at low temperatures, SN2 -type reactions can be frequently carried out; 
thus a-trichloroacetimidate yield p-glycosides. This approach was successfully used to 
generate p-2-aminoethyl glucosides and p-2-aminoethyllactosides in our lab.86 However, 
in the present study, a-2-aminoethyl mannoside 69 was obtained when glycosylation was 
effected by boron trifluoride. The difference in anomeric stereochemistry of mannosides, 
glucosides and lactosides is due to the neighbouring 2-0-acetate participation. 2-0-
Acetate protecting group interacts with the glycosyl cation and thus effectively blocks the 
p-face, leading to the formation of a-mannosides (Scheme 2.3). 
The anomeric stereochemistry of a-2-aminoethyl mannoside 69 is evident based on the 
following NOE observations: lack of NOEs between H-I' and H-3', and H-l' and H-5', 
which were observed in the p-anomers. 
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Scheme 2.2: Preparation of 2' -aminoethyl mannosides. Reagents and conditions: i, 
(AC)20, C5H5N, r.t., 24 h; ii, NH2NH2·H20, AcOH, DMF, r.t., 45 min, 64.1 % over 2 
steps; iii, ChCCN, CH2Ch, DBU, O°C, 35 min, 79.8%; iv, BF3·EhO, HOCH2CH2Cl, 
71.5%; v, NaN3, DMF, 55°C, 3 d, 95.3%; vi, NaOMe, MeOH, 30 min; vii, Pd/C, H2, H20, 
r.t., 6 h, 66.9% over 2 steps; viii, Pd/C, H2, MeOH, r.t., 6 h, quatitative . 
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Scheme 2.3: 2-0-Acetate participation in glycosylation 
The reaction between the a-2-aminoethyl mannoside 69 and diethyl squarate 57 was 
carried out in aqueous methanol solution in the presence of trace amount of triethylamine 
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86 (Scheme 2.4). The product 73 was purified by size exclusion chromatography on Bio-
Gel P2 gel eluted with milliQ water. 
OH 
o 0 Et~OEt 
57 
OH 
73 
Scheme 2.4: Synthesis of squarate-activated monovalent mannosides. Reagents and 
conditions: i, H20, MeOH, NEt3, r.t., 5 min, 41.4%. 
2.3 Synthesis of squarate-activated bivalent mannosides 
Because the interaction between glycans and their receptor lectins is relatively weak, it is 
desirable to introduce multivalent mannosides in order to enhance the cluster glycoside 
effect.9o Therefore, bivalent mannosides were synthesized in order to increase the 
binding affinity between mannosylated siRNAs and lectins. The synthesis of bivalent 
mannosides was achieved by peptide coupling of a bivalent linker 76 with acetate 
protected amino ethyl mannoside 70 (Scheme 2.6). 
Bis-carboxylic acid linker 76 was prepared in two steps in a total yield of 63% (Scheme 
2.5). Tris(2-aminoethyl)amine 74 was used as the core structure. First, one amino group 
of tris(2-aminoethyl)amine was protected by benzyloxycarbonyl (Cbz) group 75. Upon 
addition of succinic anhydride, the bis-carboxylic acid linker 76 was obtained via amide 
bond formation. 
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Scheme 2.5: Preparation of bivalent linker. Reagents and conditions: i, PhCH20COCl, 
CH2Ch, 74.4%; ii, succinic anhydride, CsHsN, 84.3%. 
Peptide coupling of the bivalent linker 76 with acetate-protected amino ethyl mannoside 
70 was first attempted using dicyclohexylcarbodiimide (DCC) as the activator and N-
hydroxy succinimide or I-hyroxyl benzotriazole (HOBT) to trap DCC-activated 
carboxylic acid. However, formation of the desired amide bond was not observed. 
(Benzotriazol-l-yloxy)tris( dimethylamino )phosphonium hexafluorophosphate (BOP) 78 
(Scheme 2.6),91 a derivative of HOBT, in the presence of the Hunig's base, led to amide 
bond formation in a moderate yield (52.5%).92 
Removal of the acetates and Cbz groups from fully-protected bivalent mannoside 77 
gave the fully-deprotected bimannoside 79 bearing a primary amino function, which was 
subsequently treated with diethyl squarate. The product, squarate-activated bivalent-
mannoside 80, was readily purified by size exclusion chromatography on a Bio-Gel P2 
column. The purified product was now ready for conjugation with oligoribonucleotides. 
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Scheme 2.6: Preparation of squarate-activated bivalent mannosides. Reagents and 
conditions i, 70, BOP, (i-Pr)2NEt, CH2Ch, 52.5%; ii, NaOMe, MeOH; iii, Pd/C, H2, 
MeOH, 96.2%; iv, H20, MeOH, NEt3, r.t., 7 min, 55.6%. 
2.4 Synthesis of oligoribonucleotides 
Oligoribonucleotides were prepared by solid phase phosphoramidite chemistry using the 
1-(4-chlorophenyl)-4-ethoxypiperidin-4-yl 41 (Cpep) to protect the 2'-hydroxyls. The 
Cpep chemistry was chosen because it allows for stable oligoribonucleotide "precursor", 
i.e. oligoribonucleotides protected at 2' -0 with Cpep, to be prepared for conjugation with 
carbohydrates. 
2-Cyanoethyl-N,N-diisopropylphophoramidites 33 are commonly used phosphoramidite 
RNA monomers. However, the coupling reactions proceed relatively slowly when the 
Cpep is used to protect the 2' -hydroxyl function due to steric hindrance (Yan, H.; Tram, 
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K. unpublished results). Previous studies in our lab have examined a senes of 
phosphoramidite derivatives from secondary amines. It was found that 2-cyanolethyl-
N,N-diethylphophoramidites as RNA monomers 88 are more reactive than the 
corresponding N,N-diisopropylphophoramidites 33 and possess reasonable shelf-lives 
(Yan, H.; Tram, K. unpublished results). In this regard, when 2-cyanolethyl-N,N-
diethylphophoramidites were used, the coupling time was effectively reduced from 10 to 
2 min. Therefore, N,N-diethylphosphoramidites 88 instead of the more traditional N,N-
diisopropylphosphoramidites 33 were used in this study. The 2' - and 5' -hydroxyls of the 
RNA monomers were protected by the Cpep 41 and DMTr 20, respectively (Scheme 2.8). 
Adenine, cytosine, and guanine residues were protected as 6-N-pivaloyladenine (b, 
Scheme 2.8), 4-N-benzoylcytosine( c, Scheme 2.8), and 2-N-phenylacetylguanine (d, 
Scheme 2.8), respectively, and uracil (a, Scheme 2.8) was left unprotected. Uridine 84a, 
4-N-benzoylcytidine 84c, and 6-N-pivaloyladenosine 84b were commercial products 
from Rasayan Inc. 2-N-Phenylacetylguanosine 83 was obtained by treatment of2',3',5'-
O-triacetyl guanosine93 82 with phenylacetyl chloride followed by deacetylation (Scheme 
2.7). 
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Scheme 2.7: Preparation of 2-N-phenylacetylguanosine. Reagents and conditions: i, 
DMF-C5H5N (2:1, v/v), (Ac)20, r.t. 1 h, then 75°C, 2 h, 85.4%; ii, phenyl acetylchloride, 
CH3CN-CsHsN (3:1, v/v), 60°C, overnight, 23.3%. 
The preparation of RNA phosphoramidite building blocks 88 is illustrated in Scheme 2.8. 
First, 5'- and 3' -hydroxyls of ribonucleosides 84 were temporarily protected with 
1,1,3,3-tetraisopropyldisiloxyl group (TIPDS) 85, followed by introduction of Cpep at 
2'-hydroxyl. After removal ofTIPDS from 86, the DMTr group was introduced at the 5'-
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position.* The 2'-O-Cpep-5'-O-DMTr ribonucleosides 87 were then converted to 
corresponding phosphoramidites 88 by treatment with 2-0-cyanoethyl-N,N-diethyl 
phosphorochloridite. 
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Scheme 2.S: Preparation of the RNA phosphoramidite building blocks. Reagents and 
conditions: i, (i-Pr)Si(Cl)OSi(Cl)(i-Pr), CsHsN, 80-90%; ii, 45c, CF3COOH, CH2Cb,; iii, 
Et4N+F-, CH3CN, 80-90% over two steps; iv, DMTr-Cl, CsHsN, >90%; v, 
CNCH2CH20P(Cl)NEt2, (i-Pr)2NEt, CH3CN, 70-90%. 
* 2' -O-Cpep-5' -O-DMTr 6-N-pivaloyladenosine and 2' -O-Cpep-5' -O-DMTr uridine were prepared by Kha 
Tram. 
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The purified 2-0-cyanoethyl-N,N-diethylphosphoramidites 88a, 88b, 88e, and 88d were 
characterized by IH and 31p NMR. The 31p NMR spectra (Figure 2.1) indicated that the 
purities of all RNA phosphoramidite building blocks are over 95% in all four cases. 
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Figure 2.1: The 31p NMR spectra of the RNA phosphoramidte building blocks 
In our study, the amino modifier linkers were chosen because they can be coupled to the 
5' -end of RNA sequences as a final step in solid-phase synthesis via phosphoramidite 
chemistry. C6-amino modifier phosphoramidite building block 92 was synthesized in two 
steps (Scheme 2.9).* In the first, the amino group of 6-amino-l-hexanol 90 was 
* Although this phosphoramidite is commercially available, we chose to prepare our own due to its 
relatively poor stability. 
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protected as trifluoroacetamide using a method reported in the literature.94 The reaction 
of 6-trifluoracetamidohexanol 91 with 2-0-cyanoethyl-N,N-
diisopropylphosphorochloridite gave the C6-amino modifier phosphoramidite 92 as a 
colorless oil after purification by column chromatography. The amino modifier amidite 
92 was analyzed by 31p NMR which indicated purity of over 98% (Scheme 2.9). 
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Scheme 2.9: Preparation of C6-amino modifier phosphoramidite building block and 31p 
NMR spectrum of 92. Reagents and conditions: i, CH2Ch, r.t., 3 h, 87.1 %; 11, 
CNCH2CH20P(Cl)N(i-Prh, (i-Pr)2NEt, CH2Ch,15 min, r.t., 57.8%. 
Oligoribonucleotide sequences were assembled by solid phase synthesis on an ABI 3400 
DNA synthesizer. After the synthesis was complete, oligoribonucleotides were cleaved 
from CPG solid supports by incubation in concentrate ammonium hydroxide at 55°C for 
12 h. This treatment also removed the cyanoethyl protecting groups for the 
intemucleotide linkages, the acyl protecting groups for the base, and the trifluoroacetyl 
protecting group for the C6-amino modifier. The crude 2' -protected RNA sequences were 
analysized by ESI-Mass. 
Several conditions were investigated for the removal of Cpep groups. Cpep groups were 
found to be completely removed under the following two conditions: (1) N,N-
dimethylacetamide (DMA)-triethylammonium formate (TEAF) buffer (pH 3.75) (2:3 
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v/v) , 12 h, 40°C; (2) DMA-TEAF buffer (pH 2.52) (3:2 v/v) , 6 h, 40°C. The latter 
condition was used in the following studies to remove the Cpep groups. 
Some physical data of synthesized oligoribonucleotides are summarized in the Table 2.1. 
U lO homo decamers were used as model RNA sequences to establish the conjugation 
chemistry. The decamers were modified at the 5'-terminus using the standard 
phosphoramidite chemistry by a C6-amino modifier 92. Amino modified UlO homo 
decamers were used to conjugate with squarate-acitived mannosides 73 and 80, 
respectively. Unmodified UlO homo decamers (UlO) 98 were used as a non-glycosylated 
control for the stability studies. AlO homo decamers (AlO) 99 were used as the 
complementary sequence to U wmers in the thermal stability studies. 
Table 2.1: Physical data ofthe oligoribonucleotides and glycoconjugates 
entry oligoribonucleotides/ Formula Rt required observed 
glycoconjugates (min) Mass Mass 
93 U9U C:207H254C19~29()s7J>9- 8.53a 5138.2 5138.5 
94 A9A C217H264C19~59()67P9 8.90a 5168.6 5368.7 
95 C6-amino modifier-U9U C213H268C19~ 30()90J> 1 0 8.52a 5317.4 5316.4 
96 Man- U9U C225H2S3C:19~31()9SJ>10- 7.63a 5618.6 5319.4 
97 Bi-Man-U9U C247 H322C19~ 36() I osP I 0- 7.34a 6152.2 6152.6 
98 UlO C90HlI0~20078J>9- 2.79b 2998.7 2998.4 
99 AlO CI00HI20~50()5SP9- 2.95b 3229.1 3229.2 
100 C6-amino modifier-U 10 C96H124~21 ()SlP10- 3.40b 3177.8 3177.7 
101 Man-UlO c: 1 osH 139~ 22()S9P I 0- 3.66b 3479.1 3479.1 
102 Bi-Man-UlO C:130HI7S~27()99PI0 2.70b 4012.7 4012.6 
~otes: (i) aRP-HPLC (C18); bAE-HPLC (D~AJ>ac PAlOO); for detailed chromatographic 
conditions, see Experimental Section. (ii) Uridine and adenosine protected by Cpep at the 
2'-()H are indicated by the italic U and A, respectively; unprotected uri dine and 
adenosine are indicated by U and A, respectively. 
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2.5 Studies of the conjugation reaction 
We then carried out conjugation reactions between squarate-activated mono- and bivalent 
mannosides and with U IO-mer bearing a C6-amino modifier. Two routes were attempted. 
First, conjugations were carried out by using amino modified UIO homo decamers 100 
(C6~amino modifier-U1o, in which all the Cpep protecting groups were removed), and the 
conjugations took place in a triethylammonium acetate buffer (TEAA, pH 8, 0.1 M). 
Second, conjugations were performed in a DMA-TEAA buffer, and amino modified U 10 
homo decamers 95 (C6-amino modifier-U9U, in which all the uridine except the 3'-
terminal one were protected by Cpep at the 2' -OR) was used as a precursor. Neither 
approach was efficient enough to give the conjugates in reasonable yields. In the first 
approach, less than 50% conversion was observed after the incubation proceeded for five 
days, as indicated by anion exchange chromatography on a DNAPac PAI00 column. The 
second route did not give any significant amount of product after 10 days. 
Addition of trace amount of triethylamine, however, accelerated the conjugation reaction 
dramatically. Thus, when Cpep-protected C6-amino modifier-U9U 95 (in Scheme 2.10) 
was treated with squarate-activated monovalent mannoside 73 in methanol-water 
containing trace triethylamine, the reaction was complete after 5 h at room temperature 
as indicated by both electrospray (ESI) mass spectrometry and reverse phase RPLC 
(Figure 2.2). 
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Scheme 2.10: Conjugation reaction of Man-U9U*. Reagents and conditions: i, MeOH, 
H20, NEt3 (U: uridine protected at 2' -position by Cpep; U: fully-unprotected uridine). 
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Figure 2.2: Stack plots of reverse phase HPLC profiles of conjugation reaction of Man-
U9D. 1). C6-amino modifier-U9U 95; 2). conjugation reaction mixture after 1 h; 3). 
conjugation reaction mixture after 3 h; 4). conjugation reaction mixture after 5 h; 5) . 
• For simplicity, Cpep-protected monomannosyl Uw-mer conjugate 96 is abbreviated as Man-U9U. 
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purified conjugate Man-U9U 96. Samples were run on C1SRP column. Linear gradient of 
0.1 M of TEAA buffer-acetonitrile (70 : 30 v/v to 20 : 80 v/v) over 15 min and then 
isocratic elution. Flow rate 1.0 ml/min. 
The chemistry was similarly efficient when the bimannoside 80 was allowed to conjugate 
with Uw-mer 95. Reverse phase HPLC profiles of the reaction mixture indicated that the 
conjugation was complete in 9 h (Figure 2.3). 
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Figure 2.3: Stack plots of reverse phase HPLC profiles of conjugation reaction of Bi-
Man-U9U*. 1). C6-amino modifier-U9U 95; 2). Conjugation reaction mixture after 3 h; 3). 
Conjugation reaction mixture after 6 h; 4). Conjugation reaction mixture after 9 h; 5). 
Purified conjugate Bi-Man-U9U 97. Samples were run on CI8 RP column. Linear gradient 
of 0.1 M of TEA A buffer-acetonitrile (70: 30 v/v to 20: 80 v/v) over 15 min and then 
isocratic elution. Flow rate 1.0 ml/min. 
• For simplicity, Cpep-protected dimannosyl Ulo-mer conjugate 97 is abbreviated as Bi-Man-U9D. 
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After the conjugations were complete, the crude conjugates were purified by semi-
preparative reverse phase HPLC and the products were identified by electro spray mass 
spectrometry. Some analytical results of the conjugates 96 and 97 are listed in Table 2.1. 
The Cpep-protected conjugates 96 and 97 were then deprotected (removal of Cpep) by 
incubation in a mixture of DMA-TEAF (PH 2.52) (3:2 v/v) to give the unprotected 
conjugates Man-UIO 101 and Bi-Man-UIO 102 (Scheme 2.11). 
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Scheme 2.11: Removal of Cpep groups. Reagents and conditions: i, (CH3)2NCONH2, 
Et3N+H-HCOO-buffer (pH 2.52), 40°C, 6 h. 
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The final mono- and bivalent conjugates 101 and 102 were identified by ESI mass 
spectrometry and analyzed by anion exchange chromatography on a DNAPac PAIOO 
column (Figure 2.4). Some physical properties of mono- and bivalent conjugates 101 and 
102 are listed in Table 2.1. These conjugates can be easily further purified by anion 
exchange chromatography if necessary. 
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Figure 2.4: Anion exchange chromatography (DNAPac PAlOO, Dionex) profiles of 
fully-deprotected conjugates. a) monomannosyl Uw-mer conjugate (Man-UlO) 101 and b) 
dimannosyl Uw-mer conjugate (Bi-Man-U10) 102. Eluent 1: TrisCl (0.1 M, pH 8.0, 10%), 
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eluent 2: water, eluent 3: NaCl (1.0 M); flow rate: 1.5 ml/min. Concave gradient ofNaCl 
from 0.1 M to 0.55 Mover 20 min. 
2.6 Stability tests 
Enzymatic stability and thermal stability tests were conducted to evaluate the impact of 
glycosylation on the stability of RNA molecules. 
2.6.1 Enzymatic stability 
The enzymatic stability tests were conducted in tris hydrochloride (Tris-Cl) buffer (pH 
8.0) with the presence of ribonuclease A (Rnase A) and bacterial alkaline phosphatase. 
Initially, the enzymatic stability tests were conducted by incubation of samples with the 
presence of stock solutions of Rnase A and bacterial alkaline phosphatase * for 24 h. It 
was found that both modified and unmodified U lO-mers were completely digested to 
uridine monomer under the above condition. In order to investigate whether the 
glycosylation has any effect on the stability of RNA molecules, a number of tests were 
conducted to establish a milder condition in which U w-mers can be digested by enzymes 
and the progress of degradation can be monitored. When the 100-fold dilution of stock 
solution of enzymes was used, the degradation progress was able to be monitored. Figure 
2.5 illustrated the progress of enzyme degradation monitored by anion exchange HPLC. 
No significant difference was observed when the enzymatic stability of mono- and 
dimannosyl UIO-mers 101 and 102 were compared with unmodified Uw-mer 98. Both the 
modified and unmodified U w-mers were digested by the enzymes at a similar rate under 
the same conditions. The effects of glycosylation on the stability of siRNA molecules 
will be investigated in the future. 
• See experimental section for the preparation of stock solution. 
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Figure 2.5: Anion exchange HPLC profiles of the enzymatic digests of UlO, Man-UlO, 
and Bi-Man-UlO. 1). (a): UlO; (b): Man-UlO; (c) Bi-Man-UlO; 2). reaction mixture after 2 
min digestion; 3). reaction mixture after 5 min digestion; 4). reaction mixture after 10 
min digestion; 5) reaction mixture after 15 min digestion. 
2.6.2 Thermal stability 
The effect of glycosylation on the duplex stability was determined by measuring the 
melting temperature. In this test, unmodified AlO-mer (AlO) was used as the 
complementary sequence; UlO:AlO is a non-glycosylated control duplex; Man-UlO:AlO and 
Bi-Man-UlO:AlO are two glycosylated conjugates. UV thermal denaturation studies of the 
umodified UlO-mers 98 and modified UlO-mer conjugates 101 and 102, revealed similar 
thermal behaviors (Figure 2.6). 
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Figure 2.6: Thermal melts on conjugates and unmodified Uw-mer. Unmodified Aw-mer 
was used as the complementary sequence. Man-UIO:AIO is indicated as AIO:mUIO, and 
Bi-Man-UIO:AlOis indicated as AlO:b-UIO in this graph. 
2.7 Synthesis of fluorescent ribosides 
Fluorescent nucleosides have been widely used as probes for hybridization, mis-matches, 
single nucleotide polymorphism etc.95, 96 Non-polar aromatic fluorescent C-nucleosides 
such as l-pyrenyl l03a and 9-phenanthrenyl deoxynucleosides l03b97 represent steric 
mimics of the natural analogs with little or no hydrogen bonding potentials. They have 
been shown to be useful tools as biophysical probes for the study of noncovalent 
interactions such as aromatic n:-stacking in DNA.97-99 
The ribonucleoside series of these non-polar aromatic fluorescent analogues l04a and 
l04b, however, have not been synthesized. With the increasing importance of 
oligoribonucleotides in applications such as RNA silencing,6 access to these compounds 
will allow for investigation of RNA-RNA and RNA-DNA interactions. 
62 
HO~r 
OH OH 
103 a; Ar :: 1-pyrenyl 104 a; Ar :: 1-pyrenyl 
b; Ar :: 9-phenanthrenyl b; Ar :: 9-phenanthrenyl 
1-pyrenyl 9-phenanth renyl 
In the present project, the sense strand of siRNA is designed to be covalently tagged with 
a fluorescent dye at the 5' -terminal for evaluation of targeting and cellular uptake of the 
mannosylated siRNAs by DCs. A convenient way to introduce a fluorescent dye is to use 
a base modified phosphoramidite, in which the base residue is replaced by a fluorophore. 
The phenanthrene and pyrene modified C-ribonucleosides (104a and 104b) were initially 
chosen as reporter groups and will be incorporated into RNA sequence through 
phosphoramidite chemistry. 
A number of approaches for the synthesis of C-nucleosides have been reported and 
recently reviewed. lOo Among these methods, the lactone approach10], 102 is efficient and 
gives good selectivity for the p-anomer. In this approach, lactone is an electrophilic sugar 
and C I-glycosidic coupling was achieved by nucleophilic attack on e1ectrophilic 
anomeric carbon in the sugar moiety. Perbenzylated lactone 110 (Scheme 2.12) has been 
employed in the preparation of C-nucleosides and C-ribonucleosides analogue by 
Leumann103 and Brownl04. Lactone derivative 105 was used by Reese et al. in the 
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synthesis of a series of C-(2' -deoxyribonucleosides ).105 This chemistry was therefore 
chosen to prepare the fully protected C-nucleosides in this study. 
o 
(i-Pf)zSi/ 
I 
0\ 
(i-Pr)zSi-O 
° 
105 
In the current study, D-ribose was used as a starting material to prepare the perbenzylated 
lactone 110 (Scheme 2.12). First, D-ribose 106 was converted to methyl D-riboside 107, 
followed by global benzylation with NaHIBnBr in dry THF to give 2,3,5-tri-O-benzyl-
methyl-D-riboside 108.106 2,3,5-Tri-O-benzyl-D-ribose 109 was obtained by acidic 
hydrolysis of corresponding methyl riboside 108.107 Modified Swem oxidation of lactol 
109 gave 2,3,5-tri-O-benzyllactone 110 in a yield of 40% over four steps. IDS 
HO~" HO~OMe BnO ii 
• ~OMe OH .. 
OH OH OH OH OBn OBn 
106 107 108 
Jiii 
Bno~o iv Bn~~ 
II OH 
OBn OBn OBn OBn 
110 109 
Scheme 2.12: Preparation of perbenzylated lactone. Reagents and conditions: i, HCl-
MeOH, r.t., 24 h, quantitatively; ii, NaH, BnBr, DMF, O°C-r.t., 24 h, 61.4%; iii, dioxane-
0.12 NHCl (4:1 v/v), reflux 9 h, 83.5%; iv, DMSO, AC20, r.t., 20 h, 79.9%. 
Bromine-lithium exchange in aromatic bromides 113 with n-butyllithium furnished aryl 
lithium which reacted in situ with perbenzylated lactone 110 at -78°C to give the 
hemiacetal intermediate 111. The hemiacetals 111 were subsequently reduced to the C-
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riboside 112 usmg triethylsilane and boron trifluoride etherate. 103 The jJ-anomeric 
isomers were isolated in moderate yields (52% and 34% for the phenanthrenyl112a and 
pyrenyl C-riboside 112b, respectively) (Scheme 2.13). 
Bn~~o ____ > Bn~o----1 OH 
'j--( Ar-Br 'j--(-"'" 
OBn OBn 113 OBn OBn 
110 111 
a; Ar = i-phenanthrene, 52% over 2 steps 
b; Ar = 9-pyrene, 34% over 2 steps 
_i_i __ ~n0\;1' 
OBn OBn 
112 
Scheme 2.13: Cl-glycosidic coupling via lactone approach. Reagents and conditions: i, 
n-BuLi, THF, -78°C, 5 h; ii, Et3SiH, Et20'BF3, -78°C, 3.5 h. 
The stereochemistry (fi-anomers) of the fully-protected C-ribosides was evident base on 
the following NOEs observation: 1). NOEs between H-3' of the ribose and the aromatic 
proton of the phenanthrene and pyrene, respectively; 2). NOEs between H-l' and H-4'; 
and 3) absence of NOEs between H-l' and H-3'. The NOEs of perbenzylated 
phenanthrene 112a is illustrated in Figure 2.7. Perbenzylated pyrene 112b showed 
similar NOE observations. 
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Figure 2.7: NOESY spectrum ofperbenzylated ,B-ribofuranosyl phenanthrene 112a 
Removal of the benzyl protecting groups from the perbenzylated ribofuranosyl 
phenanthrene 112a and pyrene 112b proved to be very challenging. Attempts to remove 
the benzyl groups by a number of approaches failed to give the desired products. Thus, 
catalytic hydrogenation, transfer hydrogenation, acid hydrolysis, and oxidative removal 
by DDQ were either extremely slow or did not give desired products. 
Boron tribromide-promoted debenzylation effected quick removal of the benzyl 
protecting groups from both perbenzylated ribofuranosyl phenanthrene 112a and pyrene 
112b (Scheme 2.14). Ribofuranosyl phenantharene 114 was obtained as an anomeric 
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mixture in 63% yield. However, ring expansion was observed in the case of the pyrene 
analogue to give an anomeric mixture of ribopyranosyl pyrene 115 in only 26% yield. In 
the latter case, no ribofuranosyl pyrenes were isolated (Table 2.2). Formation of 6-
membered ribopyranosyl pyrenes 115 was supported by the disappearance and 
appearance of 5'-OH and 4'-OH, respectively, which is clearly shown in the COSY 
spectra of both a- and ,8-anomers (Figure 2.8 and 2.9). 
HO 
Ar=pyrene 
.. 
Bno~r 
-. 0 
.. Ar=Phenan~hrene 
HO OH BnO OBn 
114 112 OH 
115 
Scheme 2.14: Debenzylation of perbenzylated ribofuranosyl phenanthrene and pyrene. 
Reagents and conditions: i, BBr3, CH2Ch, -78°C. 
Table 2.2: IH Resonance of anomeric protons in ribofuranosyl phenantharene and 
ribopyranosyl pyrene, and ratios of the anomeric isomers 
8(H-l ')(ppm) Ratio of a- and ,8-anomers * 
Ribofuranosyl phenantharene 5.41 (d, J=3.7, a-) 1: 1.84 
5.75 (d, J=2.6,,8-) 
Ribopyranosyl pyrene 5.39 (d, J=9.6,,8-) 1: 1.08 
5.41 (s, a-) 
• As determined by lH NMR of crude reaction mixture. 
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Figure 2.8: COSY spectrum of 9-a-D- ribopyranosyl pyrene 115b 
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Figure 2.9: COSY spectrum of 9-P-D- ribopyranosyl pyrene USa 
The anomeric isomers U4 and US were isolated by column chromatography and fully-
characterized. The a- and fJ-ribofuranosyl phenanthrenes were assigned based on the 
following NOE observations: 1). NOE between H-I' and 2'-OH in the fJ-anomer U4a, 
and 2). NOE between H-l' and H-3' in a-anomer U4b (Figure 2.10). Similar results 
were obtained in the debenzylated pyrene ribosides USa (fJ-anomer) and USb (a-
anomer), respectively. 
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a) b) 
HO 
HO 
c) d) 
115a 115b 
Figure 2.10: NOEs observed in the fully-deprotected ribofuranosyl phenanthrene and 
ribopyranosyl pyrene. (a) fJ-ribofuranosyl phenanthrene 114b, (b) a-ribofuranosyl 
phenanthrene 114a, (c) fJ-ribopyranosyl pyrene l1Sa, and (d) a-ribopyranosyl pyrene 
11Sb. 
The UV/vis and fluorescent emission spectroscopy of ribopyranosyl pyrene 115 and 
ribofuranosyl phenanthrene 114 (both anomers) were measured in methanol. The 
absorption and emission spectra are shown in Figure 2.11. The molar extinction 
coefficients (c), maximal absorption wavelengths ().ex), and maximal emission 
wavelengths ().em) are summarized in Table 2.3. All these compounds show weak 
fluorescent intensity. Relative fluorescent quantum yields (<Df) of these C-ribosides were 
determined against L-tryptophan using the method described in the literature. I09 
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Figure 2.11: Absorption and emission spectra of the a-ribopyranosyl pyrene llSb and 
a-ribofuranosyl phenanthrene 114b 
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Table 2.3: Molar extinction coefficients, maximal absorption wavelengths, maximal 
emission wavelengths, and fluorescent quantum yields of ribofuranosyl phenanthrene 
and ribopyranosyl pyrene 
E (M-lcm-l ) ACX(nm) Aem(nm) <Df 
a~ ribofuranosyl phenanthrene 114b 9200 251 350 0.055 
fJ- ribofuranosyl phenanthrene U4a 8350 251 350 0.062 
a~ ribopyranosyl pyrene USb 24600 335 395 0.11 
fJ- ribopyranosyl pyrene USa 25600 335 395 0.092 
L-tryptophan 5600 280 350 0.13 
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Chapter 3 - Conclusions and future work 
In conclusion, homo RNA sequences have been synthesized using Cpep as 2'-hydroxyl 
protecting group by solid phase phosphoramidite chemistry. An efficient conjugation 
chemistry has been established for the preparation of carbohydrate-RNA conjugates 
using the squarate linker. Two glycoconjugates, monomannosyl U lO-mer and dimannosyl 
UIO-mer, were synthesized using the established protocol. The effects of glycosylation on 
the stability of RNA molecules were evaluated, however no significant improvement was 
observed. 
This chemistry is currently being used to prepare carbohydrate-siRNA conjugates. In 
this conjugate, 5' - termini of sense strand of siRNA will be attached to a carbohydrate 
moiety; 5' -termini of antisense strand will be labelled with a fluorophore. Impacts of 
glycosylation on stability, binding affinity, and cellular uptake will be investigated with 
this luciferase siRNA model (Figure 3.1). 
uGl2 S' -CGUACGCGGAAUACUUCGAUU 
UUGCAUGCGCCUUAUGAAGCU -S' 
Figure 3.1: Luciferase siRNA sequence 
sense strand 
antisense strand 
In the future, a tetravalent mannoside 116 will be synthesized in order to increase lectin 
binding affinity. The bioavailability of tetramannosyl-siRNA conjugate is to be 
evaluated and compared with dimannosyl- and monomannosyl- conjugates, and 
nonglycosylated control. Ultimately, this approach may prove to be an effective way to 
improve the bioavailability of siRNAs as therapeutic agents. 
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In an attempt to prepare aromatic fluorescent ribosides, perbenzylated ribofuranosyl 
pyrene and phenanthrene were synthesized from perbenzylated ribolactone. However, 
deprotection of benzyl-protected ribofuranosyl phenanthrene and pyrene by boron 
tribromide gave ribofuranosyl phenanthrene and ribopyranosyl pyrene, respectively. 
Mechanism of this unexpected ring expansion in Lewis acid promoted debenzylation of 
perbenzylated ribofuranosyl pyrene is currently under investigation. Although 
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phenanthrene and pyrene ribosides derivatives show week fluorescent properties, they 
may be useful as probes in RNA for examination of base stacking and hydrogen bonding. 
4,4-Difluoro-4-bora-3a,4a-diaza-s-indacene (BODIPY) 117 IS a borondifluoride 
dipyrrinato complex first reported in 1968. 110 Many BODIPY derivatives display intense 
fluorescence. Work is currently in progress in our lab to develope BODIPY analogues 
into fluorophores that could be introduced into oligonucleotides using the 
phosphoramidite chemistry during solid phase synthesis. I I I, 112 
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Chapter 4 - Experimental 
General information 
IH NMR spectra were measured at 300 and 600 MHz with a Broker AV600 spectrometer; 
tetramethylsilane was used as an internal standard; J values are given in Hz. I3C NMR 
spectra were measured at 75.5 and 150.9 MHz and 31p NMR spectra were measured at 
121.5 MHz with the same spectrometer. Chemical shifts are given in ppm. Mass spectra 
were recorded on Kratos Concept IS mass spectrometer (El, FAB) and Brucker HCT 
Ultra ESI-MS spectrometer. Desican 60 A silica gel (230-400 mesh) was used for 
column chromatography. Thin layer chromatography (TLC) was performed on Silicycle 
SiliaPlate (60 A). Reverse phase high-performance liquid chromatography (HPLC) was 
carried out on a 250x4.6 mm LiChrospher 100® RP-18 5!l column: the column was 
eluted with water-acetonitrile mixtures [linear gradient of triethylammonium acetate 
buffer (0.1 M, pH 7.0)-acetonitrile (70 : 30 v/v to 20 : 80 v/v) over 15 min and then 
isocratic elution. Flow rate 1.0 mllmin]. Anion exchange chromatography was carried out 
on a 250x4 mm DNAPac® PA100 column: the column was eluted with the following 
program: eluent 1: TrisCl (0.1 M, pH 8.0, 10%), eluent 2: water, eluent 3: NaCl (1.0 M); 
flow rate: 1.5 ml/min. Concave gradient of NaCl from 0.1 M to 0.55 Mover 20 min. 
Melting points were measured with a Kofler hot-stage apparatus and are uncorrected. 
CRN analysis was performed at Guelph Chemical Laboratories Ltd (Guelph, ON) and 
Atlantic Microlab, Inc (Norcross, GA). UV absorbance was measured on Unican UV-
VIS spectrometer with Vision 32 data system. Quartz cells from Hellma Limited (10 mm 
and 1 mm path) were used for UV measurement. Fluorescence was measured by 
QuantaMaster Model QM-2001-4 cuvette based L-format scanning spectrofluorometer. 
Themal melts was performed by a Varian CARY Model 3E spectrophotometer fitted 
with a 6-sample thermostatted cell block and a temperature controller. 
Dichloromethane was purified by Pure-Solv Solvent Purification Systems (Innovative 
Technology), and stored over activated 4 A molecular sieves. Triethylamine, HOnig's 
base, and pyridine were dried by heating, under reflux, in the presence of calcium 
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hydride and then distilled under nitrogen. Uridine resin for solid phase synthesis was 
purchased from Glen Research. 1-( 4-Chlorophenyl)-4-ethoxy-l ,2,5,6-
tetrahydropiperidine and 1 ,3-dichloro-1, 1,3 ,3-tetraisopropyldisiloxane were purchased 
from Rasayan Inc. Other chemicals were purchased from Aldrich and VWR and were 
used without further purification unless stated otherwise. 
2,3,4,6-0-Tetraacetyl D-(+)-mannose 65 
OAe 
Mannose 63 (1.80 g, 10.0 romol) was dried under vacuum for 6 h and then dissolved in 
dry pyridine (30 ml), followed by addition of acetic anhydride (20.0 mI, 0.2 mmol, 20 
mol. equiv.). The reaction mixture was stirred overnight under nitrogen, and then 
quenched by addition of methanol (20 ml). The products were concentrated under 
reduced pressure. The residue was dissolved in dichloromethane (120 ml) and washed 
with saturated aqueous sodium hydrogen carbonate (100 ml). The layers were separated 
and the aqueous layer was back-extracted with dichloromethane (2x20 ml). The 
combined organic layers were dried (MgS04) and concentrated under reduce pressure. 
The residue was redissolved in ethyl acetate (2 ml) and added to hexane (100 ml) under 
stirring. The precipitate was collected by filtration to give 1,2,3,4,6-0-pentaacetyl D-
mannose as a white solid. This material was then dissolved in DMF (20 ml), followed by 
addition of hydrazine acetate (prepared by mixing 720 III of acetic acid and 600 III of 
hydrazine hydrate in 5 ml of dichloromethane, 12 mmol, 1.2 mol equiv.) at room 
temperature. After 45 min, the products were evaperated under reduced pressure. The 
residue was redissolved in dichloromethane (120 ml) and extracted with saturated 
aqueous sodium hydrogen carbonate (100 ml). The layers were separated and the 
aqueous layer was back-extracted with dichloromethane (2 x20 ml). The combined 
organic layers were dried (MgS04) and concentrated under reduce pressure. The residue 
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was purified by column chromatography on silica gel. The approprate fractions, which 
were eluted with dichloromethane-methanol (97:3 v/v) were combined and evaporated 
under reduced pressure to give the title compound as a white foam (2.23 g, 64.1 %). 
FAB-MS found ~ = 349.11642, C14H20010 requires 349.11347. 
oH[CDCh, 300 MHz]: 2.01 (3 H, s, CH3), 2.06 (3 H, s, CH3), 2.11 (3 H, s, CH3), 2.17 (3 
H, s, CH3), 3.23 (1 H, br, OH), 4.16 (1 H, m, H-6), 4.25 (1 H, m, H-5), 4.27 (1 H, m, H-
6'), 5.25 (1 H, s, H-3), 5.28 (1 H, t, J = 2.5, H-2), 5.33 (1 H, s, H-4), 5.45 (1 H, dd, J = 
3.3 and 10.1, H-l) 
Rf: 0.41 (dichloromethane-methanol, 95:5 v/v) 
2,3,4,6-0-Tetraacetyl mannosyl a-trichloroacetimidate 66 
OAe 
0yNH 
CCI3 
2,3,4,6-0-Tetraacetyl D-mannose 65 (4.69 g, 13.5 mmol) was co-evaporated with dry 
toluene (2x 10 mI) and then dissolved in dry dichoromethane (20 mI) and cooled to O°C 
(ice-water bath). Trichloroacetonitrile (23.3 mI, 0.232 mol) followed by DBU (820 /-Ll, 
5.49 mmol) were added. After 35 min, the reaction mixture was extracted with saturated 
aqueous sodium hydrogen carbonate (100 ml). The layers were separated and the 
aqueous layer was back-extracted with dichloromethane (2x20 ml). The combined 
organic layers were dried (MgS04) and concentrated under reduce pressure. The residue 
was purified by column chromatography on silica gel. The approprate fractions, which 
were eluted with toluene-ethyl acetate (3.5:1 v/v) were combined and evaporated under 
reduced pressure to give the title compound as a white glass (5.31 g,79.8%). 
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oH[CDCh, 300 MHz]: 2.02 (3 H, s, CH3), 2.08 (3 H, s, CH3), 2.09 (3 H, s, CH3), 2.21 (3 
H, s, CH3), 4.14 (1 H, m, H-6), 4.22 (l H, m, H-5), 4.29 (l H, m, H-6'), 5.41 (1 H, m, H-
3), 5.42 (l H, m, H-2), 5.48 (l H, m, H-4), 6.29 (1 H, d, J = 1.6, H-l), 8.80 (1 H, s, NH). 
8c[CDCh,75.5MHz]: 20.6 (CH3), 20.7 (CH3), 20.8 (CH3), 60.0 (CH, C-6), 65.4 (CH, C-
2), 67.8 (CH, C-4), 68.7 (CH, C-3), 71.2 (CH, C-5), 94.5 (CH, C-l), 159.7 (C, C=NH), 
169.6 (C, C=O), 169.7 (C, C=O), 169.8 (C, C=O), 170.6 (C, C=O) 
Rf : 0.50 (toluene-ethyl acetate, 3.5:1 v/v) 
2,3,4,6-0-Tetraacetyl-(2-chloroethyl)-a-D-mannoside 67 
OAe 
O~CI 
2,3,4,6-0-Tetraacetyl D-mannosyl a-trichloroacetimidate 66 (5.31 g, 10.8 mmol) was co-
evaporated with dry toluene (2x 1 0 ml) and then dissolved in dry dichoromethane (20 ml). 
Freshly distilled 2-chloroethanol (l.88 mI, 28.0 mmol) and 4 A activated molecular sieve 
powder (1.0 g) were added, and the mixture was cooled to -78°C (dry ice-acetone). To 
this solution was added a pre-cooled solution (-78°C) of boron trifluoride diethyl etherate 
(2.3 mi, 18.3 mmol) in dry dichloromethane by cannulation. After 1 h, the mixture was 
warmed up to room temperature, and then extracted with saturated aqueous sodium 
hydrogen carbonate (l00 ml). The layers were separated and the aqueous layer was back-
extracted with dichloromethane (2x20 ml). The combined organic layers were dried 
(MgS04) and concentrated under reduced pressure. The residue was purified by column 
chromatography on silica gel. The approprate fractions, which were eluted with hexane-
ethyl acetate (3:2 v/v) were combined and evaporated under reduced pressure to give the 
title compound as a white glass (3.17 g, 71.5%). 
FAB-MS found [M+Ht = 411.10556, CI6H24CIOlO+ requires 411.10580. 
oH[CDCh, 300 MHz]: 2.00 (3 H, s, CH3), 2.06 (3 H, s, CH3), 2.11 (3 H, s, CH3), 2.17 (3 
H, s, CH3), 3.67 (2 H, t, J = 5.6, OCH2ClizCl), 3.83 (1 H, dt, J = 5.3 and 10.6, 
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OClbCH2Cl), 3.93 (1 H, dt, J = 5.9 and 11.3, OClbCH2Cl), 4.12 (1 H, m, H-5), 4.16 (1 
H, m, H-6), 4.30 (1 H, m, H-6'), 4.88 (1 H, d, J = 1.1, H-1), 5.26-5.38 (3 H, m, H-2, H-3, 
and H-4) 
8c[CDCh, 300 MHz]: 20.6 (CH3), 20.7 (CH3), 20.9 (CH3), 42.4 (OCH2CH2Cl), 62.4 (C-
6), 66.0 (CH), 68.6 (OCH2CH2Cl), 68.9 (CH), 69.0 (C-5), 69.4 (CH), 97.8 (C-l), 169.8 
(C=O), 169.9 (C=O), 170.0 (C=O), 170.6 (C=O) 
Rf: 0.43 (hexane-ethyl acetate, 3:2 v/v) 
2,3,4,6-0-Tetraacetyl-(2-azidoethyl)-a-D-mannoside 68 
OAe 
o~ N3 
2,3,4,6-0-Tetraacetyl-(2-chloroethyl)-a-D-mannoside 67 (2.00 g, 4.98 mmol) was 
dissolved in DMF (30 ml) followed by addition of sodium azide (1.59 g, 24.5 mmol). 
The mixture was heated at 50°C for 3 d. The mixture was then cooled to room 
temperature and was filtered. The filtrate was concentrated. under reduced pressure and 
the residue was purified by column chromatography on silica gel. The approprate 
fractions, which were eluted with hexane-ethyl acetate (3:2 v/v) were combined and 
evaporated under reduced pressure to give the title compound as a white glass (1.94 g, 
95.3%). 
FAB-MS found [M+Ht = 418.14481, C16H24N301O+ requires 418.14617. 
oH[CDCh, 300 MHz]: 2.00 (3 H, s, CH3), 2.06 (3 H, s, CH3), 2.11 (3 H, s, CH3), 2.17 (3 
H, s, CH3), 3.48 (2 H, m, CH2), 3.68 (1 H, m, OClbCH2N3), 3.88 (1 H, m, OCH2CH2N3), 
4.05 (1 H, m, H-5), 4.13 (1 H, dd, J = 2.3 and 12.3, H-6), 4.30 (1 H, dd, J = 5.3 and 12.3, 
H-6'), 4.88 (1 H, s, H-l), 5.26-5.39 (3 H, m, H-2, H-3, and H-4) 
8c[CDCh, 75.5 MHz]: 20.6 (CH3), 20.7 (CH3), 20.8 (CH3), 20.9 (CH3), 50.3 
(OCH2CH2N3), 62.4 (CH2, C-6), 66.0 (CH), 67.0 (OCH2CH2N3), 68.8 (2xCH), 69.4 
(CH), 97.7 (CH, C-l), 169.7 (C=O), 169.8 (C=O), 170.0 (C=O), 170.6 (C=O) 
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Rf : 0.43 (hexane-ethyl acetate, 4:6 v/v) 
a-(2-Aminoethyl)-D-mannoside 69 
OH 
O~NH2 
2,3,4,6-0-Tetraacetyl-(2-azidoethyl)-a-D-mannoside 68 (0.61 g, 1.46 mmol) was 
dissolved in methanol (8.0 ml) followed by addition of a solution of sodium methoxide in 
methanol (25 wt% solution in methanol, 79 Jll, 0.36 mmol). After 30 min, pre-washed 
Amberlite IR 120 (hydrogen form) (1.45 g) was added and stirred for 2 min. The resin 
was removed by filtration and the filtrate was concentrated under reduced pressure to 
give a-(2-azidoethyl)-D-mannoside as a colorless gum (0.283 g). 
A portion of the above product (0.142 g, 0.57 mmol) was dissolved in water (10 ml) 
followed by addition of Pd/C (20.0 mg, 5% Pd on charcoal). The mixture was stirred 
under an atmosphere of hydrogen for 6 h at room temperature. The products were filtered 
through a bed of celite. The filtrate was concentrated under reduced pressure to give title 
compound as a colorless gum (0.109 g, 66.9% over two steps). 
FAB-MS found [M+Ht = 224.11771, CSH1SNO/ requires 224.11341. 
()H[D20, 300 MHz]: 2.74 (2 H, dd, J = 5.5 and 14.4, OCH2Clt2NH2), 3.44 (1 H, m, 
OClt2CH2NH2), 3.53-3.81 (6 H, m, H-3, H-4, H-5, H-6, H-6', and OClt2CH2NH2), 3.87 
(1 H, m, H-2), 4.77 (1 H, d, J = 1.6, H-l) 
()c[D20, 75.5 MHz]: 39.8 (OCH2CH2NH2), 60.9 (C-6), 66.7 (CH), 68.5 
(OCH2CH2NH2), 69.9 (C-2), 70.5 (CH), 72.7 (CH), 99.8 (C-l) 
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Monovalent mannosyl squarate 73 
OH 
HO ):( 
O~NH OEt 
a-(2-Aminoethyl)-D-mannoside (35.5 mg, 0.16 mmol) was dissolved in distilled water 
(200 ~l), followed by addition of methanol (1.8 ml), 3,4-diethoxy-3-cyclobutene-l,2-
dione (140 ~l, 0.95 mmol), and triethylamine (5 ~l). After 5 min, the solvents were 
quickly removed under reduced pressure. The residue was diluted with distilled water 
(1.0 ml) and purified by size exclusion column on Bio-Gel P2 gel (fme, 1.6 x 75 em), 
eluted with milliQ water. The appropriate fractions were combined and freeze-dried to 
give the title compound as a light yellow amorphous solid (23.0 mg, 41.4%). 
FAB-MS found [M+Ht = 348.12946, C14H22N09+ requires 348.12765 
oH[D20, 600 MHz recorded at 10°C]: 1.15 (t, J = 7.0, -OCH2Clb), 1.17 (t, J = 7.0, -
OCH2Clb) (these two signals integrate 3 H), 3.26-3.63 (10 H, m, H-2, H-3, H-4, H-5, H-
6, H-6', and CH2), 4.44 (q, J= 7, -OCH2CH3), 4.47 (q, J= 7, -OCH2CH3) (these two 
signals integrate 2 H), 4.58 (1 H, d, J = 6.0, H-l) 
Rf: 0.69 (chloroform-methanol-water, 65:35:5 v/v) 
2-(Benzyloxycarbonyl)tris(2-aminoetbyl)amine 75 
~NH2 
~ HN~N,\ 
- 0-\ NH2 
o 
Tris(2-aminoethyl)amine 73 (2.92 g, 20.0 mmol) was dissolved in dry dichloromethane 
(50 ml) and cooled (ice-water bath). A solution of benzyl chloroformate (1.03 ml, 7.22 
mmol) in dry dichloromethane (100 ml) was added over a period of 1 h. The mixture was 
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allowed to warm up to room temperature slowly. After an additional 1 h, the solvent was 
removed under reduced pressure. The residue was purified by column chromatography 
on silica gel. The approprate fractions, which were eluted with chloroform-methanol-
amonium hydroxide (10:4: 1 v/v) were combined and evaporated under reduced pressure 
to give the title compound as a yellow oil (1.25 g, 61.8% based on benzyl chloroformate). 
FAB-MS found [M+Ht = 28l.19946, C14H25 N402+ requires 281.19775. 
8H [CDCh, 300 MHz]: 2.51 (4 H, t, J = 6, -NCH2CHzNH2), 2.56 (2 H, t, J = 5.9, CH2), 
2.72 (4 H, t, l. = 6, -NCHzCH2NH2), 3.26 (2 H, br, CH2), 4.78 (4 H, br, NH2), 5.10 (2 H, s, 
-CH2Ph), 6.05 (1 H, br, NH), 7.31-7.37 (5 H, m, Ar) 
8c[CDCh, 75.5 MHz]: 39.4 (CH2), 39.6 (CH2)' 53.7 (CH2), 57.0 (CH2), 66.5 (CH2), 
128.0 (CH), 128.1 (CH), 128.5 (CH), 136.8 (C), 156.7 (C=O). 
Rf : 0.22 (chloroform-methanol-ammonium hydroxide, 10: 4:1 v/v) 
2,2' -Bissuccinoyl-2" -(benzyloxycarbonyl)tris(2-aminoethyl)amine 76 
OH 
HN 
r o 
O~ HN~\\ 0 
- o-{ HN 
o 
OH 
2-(Benzyloxycarbonyl)tris(2-aminoethyl)amine 75 (1.88 g, 6.71 mmol) was co-
evaporated with dry toluene (2x 10 ml) and then dissolved in dry pyridine (30 ml). 
Succinic anhydride (1.47 g, 14.7 mmol) was added at room temperature. After 40 min, 
the products were concentrated under reduced pressure. The residue was dissolved in 
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methanol (5 ml) and added drop-wise to diethyl ether (300 ml) under stirring. The 
product was collected by filtration as a white amorphous solid (2.71 g, 84.1 %). 
ESI-MS found [M-H]-= 479.2, C22H3IN40 8- requires 479.2. 
bH[D20, 600 MHz]: 2.37 (4 H, t, J = 6.0, CH2), 2.41 (4 H, t, J = 6.2, CH2), 3.26 (6 H, m), 
3.39 (5 H, m), 5.01 (2 H, -CH2Ph), 7.25-7.40 (5 H, Ar) 
Rf : 0.12 (chloroform-methanol-ammonium hydroxide, 10: 4: 1 v/v) 
Trifluoroacetate salt of 2,3,4,6-0-tetraacetyl-(2-aminoethyl)-a-D-mannoside 70 
OAe 
AcO 
~N+H;TFA 
2,3,4,6-0-Tetraacetyl-(2-azidoethyl)-a-D-mannoside 68 (600.00 mg, 1.44 mmol) was 
dissolved in methanol (25 ml) followed by addition of Pd/C (42.00 mg, 5% Pd on 
charcoal) and trifluoroacetic acid (200 Ill, 2.65 mmol). The reaction mixture was stirred 
under an atmosphere of hydrogen for 5 h at room temperature. The products were filtered 
through a bed of celite. The filtrate was concentrated under reduced pressure and used for 
the next reaction without further purification. 
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Fully-protected bivalent mannoside 77 
A,o~I~\ 
Aeo~ 
~N~ 
H )-NH O}-cf < ) 
° \ NH 
OAe ~~ Aeo~I~~\ -(}-O r Aeo~ NH 
O~N 
H 
° 
2,2' -Bissuccinoyl-2" -(benzyloxycarbonyl)tris(2-aminoethyl)amine 76 (0.230 g, 0.48 
mmol) was dissolved in dry dichloromethane (10 ml). Then (benzotriaz01-1-
yloxy)tris(dimethylamino)phosphonium hexafluorophosphate (BOP) (0.424 g, 0.96 
mmol) followed by Hiinig's base (0.75 mI, 4.31 mmol) were added at room temperature. 
After 20 min, a solution of the trifluoroacetate salt of 2,3,4,6-0-tetraacetyl-(2-
aminoethyl)-a-D-mannoside 70 (1.44 mmol, prepared as described above) in dry 
dichloromethane (5 ml) was added. The reaction was allowed to proceed at room 
temperature for 12 h. The products were then concentrated under reduced pressure. The 
residue was purified by column chromatography on silica gel. The appropriate fractions, 
which were eluted with dichloromethane-methanol (95:5 v/v) were combined and 
evaporated under reduced pressure to give the title compound as a white glass (0.309 g, 
52.5%). 
FAB-MS found [M+Ht = 1227.60795, CS4H79026N6 requires 1227.50441 
oH[CDCh, 300 MHz]: 2.01 (CH3), 2.07 (CH3), 2.12 (CH3), 2.17 (CH3), 4.00 (2 H, br, H-
5man), 4.12 (2 H, dd, J = 2.0 and 12.0, H-6man), 4.29 (2 H, dd, J = 5.0 and 12.0, H-
6'man), 4.82 (2 H, s, H-1man), 5.10 (2 H, s, -CH2Ph), 5.28-5.31 (6 H, br, m, H-2, H-3, 
H-4man), 7.36 (5 H, Ar). 
Rf : 0.51 (dichloromethane-methanol, 90:10 v/v) 
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FuHy-deprotected bivalent mannoside 78 
±J;0H O~O HO 
HO 
~~. 
~NH 
o ~ ;--NH2 
OH N~ Ho~I~O\ -?o r HO~ NH 
O~N 
H 
o 
Fully-protected bivalent mannoside 77 (0.194 g, 0.158 mmol) was dissolved in methanol 
(3 ml) followed by addition of a solution of sodium methoxide in methanol (25 wt%, 9 Ill, 
0.042 mmol). After 1 h, pre-washed Amberlite IR 120 resin (hydrogen form, 300 mg) 
was added and stirred for 5 min. The resin was removed by filtration and the filtrate was 
concentrated under reduced pressure. The residue was redissolved in methanol (15 ml) 
followed by addition of Pd/C (30.0 mg, 5% Pd on charcoal). The reaction mixture was 
stirred in an atmosphere of hydrogen at room temperature for 3 h. The products were 
filtered through a bed of celite. The filtrate was concentrated under reduced pressure and 
the residue was purified by size exclusion column on Bio-Gel P2 (fine, 1.6 x 75 em), 
eluted with aqueous ammonium bicarbonate buffer (30 mM). The appropriate fractions 
were combined and freeze-dried to give the title compound as a colorless glass (0.115 g, 
96.2%). 
FAB-MS found [M+Ht = 757.40622, C30H58016N/ requires 757.38311 
bH[D20, 600 MHz]: 2.66 (8 H, s, br, CH2), 2.80 (4 H, s, br, CH2), 2.85 (2 H, s, br, CH2), 
3.05 (2 H, s, br, CH2), 3.41 (4 H, s, br, CH2), 3.50-3.53 (2 H, m, H-6), 3.57-3.60 (2 H, 
m, H-6'), 3.71-3.75 (4 H, m, CH2and H-5), 3.78 (2 H, t, J= 9.6, H-4), 3.86-3.93 (6 H, 
m, CH2 and H-3), 4.01 (2 H, d, J= 12, CH2), 4.07 (2 H, s, H-2), 4.99 (2 H, s, H-1). 
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8c[D20, 150.9 MHz]: 31.2 (CH2), 31.3 (CH2), 37.2 (CH2), 39.2 (C-6), 52.62 (CH2), 61.2 
(CH2), 66.1 (CH2), 67.0 (C-4), 70.3 (C-2), 70.8 (C-3), 73.1 (C-5), 99.9 (C-l), 175.0 
(C=O). 
Rr: 0.20 (methanol-ammonium hydroxide, 4: 1 v/v) 
Squarate-activated bivalent-mannoside 80 
±J;0H O~ HO 
HO 
~N-\-H a N~ r-):(EI 
OH N~ Ho~I~O\ --\0)-r HO~ NH 
O~N 
H 
o 
Bivalent mannoside 79 (17.9 mg, 23.7 Ilmo1) was dissolved in distilled water (100 Ill), 
followed by addition of methanol (900 Ill), 3,4-diethoxy-3-cyclobutene-l,2-dione (21 Ill, 
142 Ilmol), and triethylamine (3 Ill). After 7 min, the solvents were quickly removed 
under reduced pressure. The residue was diluted with distilled water (1.0 ml) and purified 
by size exclusion column on Bio-Gel P2 resin (fine, 1.6 x 75 em), eluted with milliQ 
water. The appropriate fractions were combined and freeze-dried to give the title 
compound as a light yellow amorphous solid (11.6 mg, 55.6%). 
FAB-MS found [M+Ht = 881.38400, C36H61019N/ requires 881.39915 
8H[D20, 600 MHz recorded at 5°C]: 1.07 (t, J = 7.2, -OCH2C[i3), 1.08 (7, J = 7.2, -
OCH2CH3) (these two signals integrate 3 H), 2.16-2.18 (8 H, m, br, CH2), 2.36 (4 H, s, 
br, CH2), 2.45 (2H, s. br, CH2), 2.94 (4 H, s, br, CH2), 2.99-3.02 (2 H, m, H-6), 3.09-
3.12 (2 H, m, H-6'), 3.19-3.30 (6 H, m, H-4, H-5, and CH2), 3.35-3.45 (6 H, m, H-3 and 
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CH2), 3.51 (2 H, d, J= 12.0, CH2), 3.57 (2 H, s, br, H-2), 4.35 (q, J= 7.1, -OCH2CH3), 
4.39 (q, J = 7.1, -OClbCH3) (these two signals integrate 2 H), 4.49 (2 H, s, H-l). 
Rr: 0.45 (methanol-ammonium hydroxide, 4: 1 v/v) 
3' ,5' -0-(1,1,3,3-Tetraisopropyldisiloxy)-4-N-benzoylcyddine S5e 
HN~ c~l) ('P)s./oq ° 1- r 2 I ° I 
0\ 
(i-PrhSi--O OH 
4-N-Benzoylcytidine S4c (5.22 g, 15.0 mmol), which had been dried at 90°C in vacuo for 
6 h, was co-evaparated with dry pyridine (2x 10 ml). The residue was redissolved in dry 
pyridine (50 ml) and cooled to O°C followed by addition of 1,3-dichloro-l,1,3,3-
tetraisopropyldisiloxane (5.24 g, 16.6 mmol, 1.1 mol equiv.). After stirring at O°C for 30 
min, the mixture was warmed up to room temperature and stirred for another 3.5 h. Then 
water (5 ml) was added, and after 5 min, the products were concentrated under reduced 
pressure. The residue was dissolved in dichloromethane (120 ml) and washed with 
saturated aqueous sodium hydrogen carbonate (100 ml). The layers were separated and 
the aqueous layer was back-extracted with dichloromethane (2x20 ml). The combined 
dried (MgS04) organic layers were concentrated under reduced pressure and the residue 
was purified by column chromatography on silica gel. The approprate fractions, which 
were eluted with dichloromethane-methanol (98:2 v/v) were combined and evaporated 
under reduced pressure to give the title compound as a white glass (6.71 g, 75.8%). 
FAB-MS found [M+Ht = 590.27355, C28H4307N3Sh + requires 590.27178. 
8H[(CD3hSO, 600 MHz]: 0.97-1.08 (28 H, m, CH3 and CH), 3.95 (1 H, d, J = 13.1, H-
5'), 4.11 (3 H, s, H-2, H-3, and H-4), 4.24 (1 H, d, J = 13.4, H-5"), 5.82 (1 H, d, J = 3.7, 
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H-l '), 7.37 (1 H, d, J = 7.5, H-5), 7.52 (2 H, t, J = 7.7, CH), 7.63 (1 H, t, J = 7.4, CH), 
8.01 (2 H, d, J = 7.7, CH), 8.21 (1 H, d, J = 7.4, H-6), 11.29 (1 H, s, NH). 
oc[(CD3)2S0, 150.9 MHz]: 12.3-13.2 (CH3), 17.2-17.9 (CH), 60.3 (CH2, C-5'), 68.5 
(CH), 74.3 (CH), 81.4 (CH), 91.8 (CH, C-l '), 96.0 (CH, C-5), 128.9 (CH), 133.2 (CH), 
144.2 (CH, C-6), 154.6 (C), 163.6 (C), 167.8 (C), 206.9 (C, C=O) 
Rf: 0.53 (dichloromethane-methanol, 95:5 v/v) 
2' -0-[1-( 4-Chlorophenyl)-4-ethoxypiperidin-4-yl]-4-N-benzoylcyddine S6c 
HN~ CNU 
HO I N~O 
~ 
OH OCpep 
3' ,5' -0-(1,1,3,3-Tetraisopropyldisiloxy)-4-N-benzoylcytidine SSe (6.50 g, 11.0 mmol) 
and 1-(4-chlorophenyl)-4-ethoxy-l,2,5,6-tetrahydropiperidine (7.87 g, 33.1 mmol, 3 mol 
equiv.) were co-evaporated with dry toluene (2x 10 ml) and then dissolved in dry 
dichoromethane (40 ml), followed by addition of freshly distilled trifluoroacetic acid (2.1 
mI, 20.0 mmol, 2 mol equiv.). After 6 h, triethylamine (3.0 mI, 31.4 mmol, 3 mol equiv.) 
was added and the products were partitioned between dichloromethane (l00 ml) and 
saturated aqueous sodium hydrogen carbonate (l00 ml). The layers were separated and 
the dried (MgS04) organic layer was concentrated under reduced presure. The residue 
was taken up with acetonitrile (30 ml) followed by addition of a solution of tetraethyl 
ammonium fluoride in acetonitrile (40 mI, 2.2 mol equiv., 1.0 M, pH 8.0). After 30 min, 
the products were concentrated under reduced pre sure and the residue was purified by 
column chromatography on silica gel. The appropriate fractions, which were eluted with 
dichloromethane-methanol (97:3 v/v) were collected and concentrated under reduced 
pressure to give the title compound as a white glass (5.08 g, 79.1 %). 
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F AB-MS found M+ = 584.20269, C29H33CI07N/ requires 584.20378. 
oH[(CD3)2S0, 600 MHz]: 0.90-0.94 (3 H, m, CH3), 1.73-1.91 (4 H, m, CH2), 2.88 (1 H, t, 
J = 9.5, CH2), 3.01 (1 H, t, J = 9.5, CH2), 3.17 (1 H, m, CH2), 3.26 (1 H, m, CH2), 3.38 
(1 H, m, CH2), 3.45 (1 H, m, CH2), 3.63 (l H, m, H-5'), . 3.67 (1 H, m, H-5"), 3.98 (1 
H, d, J= 2.2, H-4'), 4.05 (1 H, m, H-3'), 4.44 (1 H, d, J= 5.9, H-2'), 5.18 (1 H, d, J= 
5.0,3'-OH), 5.30 (l H, t, J= 4.9, 5'-OH), 6.15 (1 H, d, J= 6.7, H-l'), 6.91 (2 H, d, J= 
9.0, CH2), 7.18 (2 H, d, J = 8.9, CH2), 7.41 (1 H, br, H-5), 7.52 (2 H, t, J = 7.7, CH), 
7.63 (1 H, t, J = 7.4, CH), 8.01 (2 H, d, J = 7.7, CH), 8.49 (1 H, br, H-6), 11.31 (1 H, br, 
NH). 
Oc[(CD3)zSO, 150.9 MHz]: 13.1 (CH3), 15.5 (CH), 32.4 (CH2 ), 33.7 (CH2), 45.9 (CH2), 
46.2 (CH2), 55.4 (CH2), 56.5 (CH2), 61.8 (CH, C-5'), 7l.2 (CH, C-3'), 74.1 (CH, C-2'), 
86.9 (CH, C-4'), 87.8 (CH, C-l'), 98.7 (CH, C-5), 117.6 (CH), 122.4 (CH), 128.7-129.4 
(CH), 146.2 (CH, C-6) 
Rf : 0.48 (dichloromethane-methanol, 95:5 v/v) 
2' -0-[1-( 4-Chlorophenyl)-4-ethoxypiperidin-4-yl]-5' -0-(4,4' -dimethoxytrityl)-4-N-
benzoylcytidine 87c 
HN~ CNV 
DMTrO I N~O ~ 
OH OCpep 
2' -0-[ 1-( 4-Chlorophenyl)-4-ethoxypiperidin-4-yl]-4-N-benzoylcytidine 86c (5.32 g, 9.1 
mmol) was co-evaporated with dry pyridine (2 x 5 ml). The residue was redissolved in dry 
pyridine (45 ml) followed by addition of 4,4'-dimethoxytrityl chloride (3.39 g, 10.0 
mmol, 1.1 mol equiv.). After 40 min, triethylamine (5 ml) was added. After another 10 
min, the products were partitioned between dichloromethane (100 ml) and saturated 
aqueous sodium hydrogen carbonate (100 ml). The layers were separated and the dried 
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(MgS04) organic layer was concentrated under reduced presure. The residue was purified 
by column chromatography on silica gel. The appropriate fractions, which were eluted 
with dichloromethane-methanol (98.5:1.5 v/v) , were collected and concentrated under 
reduced pressure to give the title compound as a yellow glass (7.71 g, 95.4%). 
FAB-MS found M+ = 886.32870, CSOHSICI09N/ requires 886.33446 
bH[(CD3)2S0, 600 MHz]: 0.99 (3 H, t, J= 6.9, CH3), 1.78-1.94 (4 H, m, CH2), 2.96 (1 H, 
t, J= 9.5, CH2), 3.06 (1 H, t, J= 9.2, CH2), 3.24-3.31(3 H, m, CH2), 3.40-3.43 (2 H, m, 
CH2), 3.57 (1 H, t, J = 7.7, CH2), 3.75 (6 H, s, 2xCH3), 4.11 (1 H, d, J = 2.9, H-4'), 4.22 
(1 H, d, J = 4.1, H-3'), 4.59 (1 H, t, J = 5.4, H-2'), 5.31 (1 H, d, J = 5.9, 3' -OH), 6.15 (1 
H, d, J = 5.5, H-1 '),6.92-6.95 (6 H, m, Ar), 7.19 (3 H, d, J = 9.0, Ar and H-5), 7.29 (5 H, 
m, Ar), 7.35 (2 H, t, J = 7.6, Ar), ,7.42 (2 H, d, J = 7.7, Ar), 7.52 (2 H, t, J = 7.7, Ar), 
7.63 (1 H, t, J = 7.4, Ar), 8.01 (2 H, d, J = 7.6, Ar), 8.25 (1 H, d, J = 7.3, H-6), 11.34 (l 
H, s, NH). 
8c[(CD3)2S0, 150.9 MHz]: 15.5 (CH3), 32.8 (CH2), 33.5 (CH2), 46.1 (CH, C-5'), 55.5 
(CH2 and CH3), 63.8 (CH2), 70.8 (CH, C-3'), 74.0 (CH, C-2'), 84.5 (CH, C-4'), 86.7 (CH, 
C-l '), 100.0 (CH, C-5), 113.1-136.5 (CH), 144.9 (CH, C-6) 
Rf: 0.54 (dichloromethane-methanol, 95:5 v/v) 
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2' -0-[1-( 4-Chlorophenyl)-4-ethoxypiperidin-4-yl]-5' -0-(4,4' -dimethoxytrityl)-
4-N-benzoylcyddine 3'-(2-0-cyanoethyl) N,N-diethylphosphoramidite SSe 
HN~ CNU 
DMTrO I NAO ~ NC~O'-.... /0 OCpep 
f (I 
2' -0-[1-( 4-Chlorophenyl)-4-ethoxypiperidin-4-yl]-5' -0-(4,4' -dimethoxytrityl)-4-N-
benzoylcytidine S7c (2.00 g, 2.25 mmol) was co-evaporated with dry toluene(2x 5 ml). 
The residue was redissolved in dry THF (30 ml) followed by addition of N,N-
diisopropylethylamine (978 Ill, 5.63 mmol, 2.5 mol equiv.). After 5 min, 2-0-
cyanoethyl-N,N-diethyl phosphorochloridite1l3 (0.94 g, 4.51mmol, 2 mol equiv.) was 
added. After 3 h, the solvent was removed under reduced pressure. The residue was 
purified by column chromatography on silica gel. The appropriate fractions, which were 
eluted with hexane-acetone-triethylamine (65:30:2 v/v) were collected and concentrated 
under reduced pressure to give the title compound as a light yellow glass (2.06 g, 85.5%). 
()H[CDCh, 300 MHz]: 4.25 (s, H-4'), 4.37 (s, H-4') (these two signals integrate 1 H), 
4.51 (1 H, m, H-3'), 4.87 (dd, J = 4.6 and 6.5, H-2'), 4.87 (dd, J =5.1 and 6.5, H-2') 
(these two signals integrate 1 H), 6.42 (d, J =7.0, H-l '),6.45 (d, J = 6.5, H-l') (these two 
signals integrate 1 H), 7.02 (d, J = 7.5, H-5), 7.03 (d, J = 7.5, H-5) (these two signals 
integrate 1 H), 8.22 (d, J = 7.5, H-6), 8.25 (d, J = 7.6, H-6) (these two signals integrate 1 
H), 6.81-7.93 (22 H, Ar). 
()p[CDCh,121.5 MHz]: 149.22 and 150.13 
Rf: 0040 (hexane-acetone-triethylamine, 65:30:2 v/v) 
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2' ,3' ,5'-0-Triacetyl guanosine 82 
o 
N < I NH 
OAe OAe 
Guanosine 81 (8.50 g, 30.0 mmol) was co-evaporated successively with dry toluene 
(2x lO ml) and dry pyridine (10 ml). The residue was dissolved in dry DMF (35 ml) and 
dry pyridine (15 ml), followed by addition of acetic anhydride (18 mI, 0.19 mol, 6 mol. 
equiv.). The mixture was stirred at room temperature for 1 h, and then heated at 75° C for 
2 h. Then the reaction mixture was cooled to room temperature and quenced by addition 
of methanol (20 ml). The mixture was then concentrated to ca. 112 of the original volume 
under reduced pressure to yield a white precipitate. The solid was isolated by filtration. 
The filtrate was further concentrated under reduced pressure until white solid precipated 
out of solution. The products from the two crops were combined to yield 2',3',5' -0-
triacetyl guanosine as a white solid (10.49 g, 85.4%). 
oH[(CD3)2S0, 300 MHz]: 2.04-2.11 (9 H, m, CH3), 4.28-4.35 (3 H, m, H-4', H-5' and H-
5"),5.50 (1 H, m, H-3'), 5.79 (1 H, t, J = 6.0, H-2'), 5.98 (1 H, d, J = 6.2, H-l '),6.53 (2 
H, s, NH2), 7.93 (1 H, s, H-8), 10.73 (l H, br, NH). 
Rf: 0.64 (dichloromethane-methanol, 90:10 v/v) 
2-N-Phenylacetylguanosine 83 
o 
{i:;: 9 ~ H~o.J N N~ HH 
OH OH 
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2',3',5'-O-Triacetyl guanosine 82 (10.49 g, 25.6 mmol) was co-evaporated with dry 
toluene (2x 10 ml), and then dissolved in acetonitrile (140 ml) and dry pyridine (40 ml). 
The mixture was stired for 10 min and cooled to O°C. A solution of phenyl acetyl chloride 
(9.0 mI, 64 mmo!, 2.5 mol equiv.) in acetonitrile (30 ml) was added to the above mixture 
over a period of 30 min at O°C. This reaction mixture was stirred at room temperature for 
1 h and then at 60°C overnight. The reaction was quenched by addition of ice-water (5 
ml), followed by addition of toluene (100 ml), and shaked overnight. The organic layer 
was isolated and concentrated under reduced pressure. The yellow froth residue was 
dissolved in methanol (140 ml) and cooled to O°C. Cold NaOH solution (2 M, 86 ml) was 
added over 5 min. The mixture was stirred at O°C for 10 min, and was then neutralized 
by addition of hydrochloric acid (2 AI) to pH 6. After addition of ethyl acetate (100 ml), 
the percipitate was collected by filtration to give the 2-N-phenylacetyl guanosine (2.39 g, 
23.3%). 
()H[(CD3)2S0, 300 MHz]: 3.81 (2 H, s, CH2), 3.57 (1 H, m, H-5'), 3.63 (1 H, m, H-5"), 
3.91 (1 H, m, H-4'), 4.13 (1 H, t, J = 3.9, H-3'), 4.44(1 H, t, J = 5.1, H-2'), 5.05 (1 H, t, 
J= 5.l, 5'-OH), 5.18 (1 H, s, 3'-OH), 5.48 (1 H, s, 2'-OH), 5.81 (1 H, d,J= 5.8, H-l'), 
7.27-7.35 (5 H, m, CH), 8.26 (1 H, s, H-8), 11.98 (1 H, s, NH). 
Rf : 0.32 (dichloromethane-methanol, 95:5 v/v) 
2-N-Phenylacetyl-3' ,5' -O-(1,1,3,3-tetraisopropyldisiloxy)guanosine 85d 
o 
(NY'7H \I ~ 
o N--l .. ~~
(i-Pr) Si/ ~ N N 2 I 0 H 
0\ 
(i-PrhSi--O OH 
2-N-Phenylacetylguanosine 83 (5.59 g, 13.9 mmol), which had been dried at 80°C in 
vacuo for 6 h, was co-evaparated with dry pyridine. The residue was redissolved in dry 
pyridine (60 ml) and cooled to O°C followed by addition of 1,3-dichloro-l,1,3,3-
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tetraisopropyldisiloxane (4.83 g, 15.3 mmol, 1.1 mol equiv.). After stirring at O°C for 30 
min, the mixture was warmed up to room temperature and stirred for another 3 h. Then 
water (5 ml) was added, and after 10 min, the products were concentrated under reduced 
pressure. The residue was dissolved in dichloromethane (120 ml) and washed with 
saturated aqueous sodium hydrogen carbonate (100 ml). The layers were separated and 
the aqueous layer was back-extracted with dichloromethane (2 x20 ml). The combined 
dried (MgS04) organic layers were concentrated under reduced pressure and the residue 
was purified by column chromatography on silica gel. The approprate fractions, which 
were eluted with dichloromethane-methanol (97.5:2.5 v/v) were combined and 
evaporated under reduced pressure to give the title compound as a colourless froth (6.73 
g,75.2%). 
oH[(CD3)2S0, 300 MHz]: 1.03-1.06 (28 H, m, CH and CH3, i-Pr), 3.82 (2 H, s, CH2), 
3.96 (1 H, dd, J= 2.3 and 12.8, H-5'), 4.06 (1 H, m, H - 3'), 4.15 (1 H, dd, J= 3.0 and 
12.8, H-5"), 4.34 (1 H, m, H-2'), 4.37 (l H, m, H-4'), 5.71 (l H, d, J = 4.6, H-l '),5.81 
(l H, s, 2'-OH), 7.27-7.35 (5 H, m, CH), 8.05 (l H, s, H-8), 11.98 (l H, s, NH), 12.03 (1 
H, s, NH). 
Rf: 0.50 (dichloromethane-methanol, 95:5 v/v) 
2' -0- [1-( 4-Chlorophenyl)-4-ethoxypiperidin-4-yl]-2-N-phenylacety19uanosine 86d 
(NLJ: ~ ~ HO~a-J ~ N~ KH 
OH OCpep 
2-N-Phenylacetyl-3',5'-O-(l,1,3,3-tetraisopropyldisiloxy)guanosine 85d (6.73 g, 10.4 
mmol) and 1-(4-chlorophenyl)-4-ethoxy-l,2,5,6-tetrahydropiperidine (5.69 g, 24 mmol, 
2.3 mol equiv.) were co-evaporated with dry toluene (2x lO ml) and then dissolved in dry 
dichoromethane (60 m!), followed by addition of freshly distilled trifluoroacetic acid 
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(2.08 mI, 27 mmol, 2.6 mol equiv.). After 6 h, triethylamine (4.4 mI, 31.4 mmol, 3 mol 
equiv.) was added and the products were partitioned between dichloromethane (100 ml) 
and saturated aqueous sodium hydrogen carbonate (l00 ml). The layers were separated 
and the dried (MgS04) organic layer was concentrated under reduced presure. The 
residue was taken up with acetonitrile (30 ml) followed by addition of a solution of 
tetraethyl ammonium fluoride in acetonitrile (25 mI, 2.2 mol equiv., 1.0 M, pH 8.0). 
After 1.5 h, the products were concentrated under reduced pre sure and the residue was 
purified by column chromatography on silica gel. The appropriate fractions, which were 
eluted with dichloromethane-methanol (96:4 v/v) were collected and concentrated under 
reduced pressure to give the title compound as a yellow froth (5.97 g, 89.8%). 
8H[(CD3)2S0, 300 MHz]: 0.76 (3 H, t, J = 6.9, CH3), 1.62 (2 H, m, CH2), 1.82 (2 H, m, 
CH2), 2.79 (2 H, m, CH2), 3.66 (2 H, m, H - 5' and H - 5"), 3.80 (2 H, s, CH2), 4.01 (l 
H, t, J = 3.1, H-4'), 4.13 (l H, t, J = 4.1, H-3'), 4.73 (1 H, m, H-2'), 5.16 (1 H, d, J = 4.0, 
3' -OH), 5.22 (1 H, t, J = 5.1, 5' -OH), 5.98 (1 H, d, J = 7.5, H-l '), 6.82 (2 H, d, J = 9.0, 
CH), 7.12 (2 H, d, J = 9.0, CH), 7.27-7.35 (5 H, m, CH), 8.35 (l H, s, H-8), 11.90 (l H, 
s, NH), 11.98 (1 H, s, NH). 
Rr: 0.51 (dichloromethane-methanol, 90:10 v/v) 
2' -0-[1-( 4-Chlorophenyl)-4-ethoxypiperidin-4-yl]-5' -0-(4,4' -dimethoxytrityl)-2-N-
phenylacetylguanosine 87d 
o 
(I NH 0 p7 I 
o H 
OH OCpep 
2' -0-[1-( 4-Chlorophenyl)-4-ethoxypiperidin-4-yl]-2-N-phenylacetylguanosine 86d 
(5.90 g, 9.23 mmol) was co-evaporated with dry pyridine (2x5 ml). The residue was 
redissolved in dry pyridine (50 ml) followed by addition of 4,4' -dimethoxytrityl chloride 
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(3.44 g, 10.15 mmol). After 45 min, triethylamine (5 ml) was added. After another 10 
min, the products were partitioned between dichloromethane (l00 ml) and saturated 
aqueous sodium hydrogen carbonate (l00 ml). The layers were separated and the dried 
(MgS04) organic layer was concentrated under reduced presure. The residue was purified 
by column chromatography on silica gel. The appropriate fractions, which were eluted 
with dichloromethane-methanol (96:4 v/v) were collected and concentrated under 
reduced pressure to give the title compound as a yellow froth (8.45 g, 97.4%). 
8H[(CD3)2S0, 300 MHz]: 0.76 (3 H, t, J= 6.9, CH3), 3.73 (6 H, s, CH3), 4.12 (l H, s, H-
4'),4.21 (l H, s, H-3'), 4.92 (1 H, t, J= 6.0, H-2'), 5.28 (l H, d, J= 4.5, 3'-OH), 6.01 (1 
H, d, J = 7.1, H-l '),8.08 (1 H, s, H-8), 6.83-7.42 (22 H, Ar), 11.8 (1 H, br, NH). 
Rf: 0.33 (dichloromethane-methanol, 95:5 v/v) 
2' -0- [1-( 4-Chlorophenyl)-4-ethoxypiperidin-4-yl]-5' -0-(4,4' -dimethoxytrityl)-2-N-
phenylacetyl-guanosine-3' -(2-0-cyanoethyl) N ,N-diethylphosphoramidUe 88d 
o 
(I NH 0 P' I 
o H 
2' -0-[1-( 4-Chlorophenyl)-4-ethoxypiperidinA-yl]-5' -0-(4,4' -dimethoxytrityl)-2-N-
phenylacetylguanosine 87d (1.00 g, 1.06 mmol) was co-evaporated with dry toluene 
(2x5 ml). The residue was redissolved in dry THF (18 ml) followed by addition of N,N-
diisopropylethylamine (739 Ill, 4.25 mmol, 4 mol equiv.). After 10 min, 2-0-cyanoethyl-
N,N-diethyl phosphorochloridite phosphorochloridite (0.44 g, 2.12 mmol, 2 mol equiv.) 
was added. After 1 h, the solvent was removed under reduced pressure. The residue was 
purified by column chromatography on silica gel. The appropriate fractions, which were 
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eluted with hexane-acetone-triethylamine (50:50:2 v/v) were collected and concentrated 
under reduced pressure to give the title compound as a light yellow glass (0.70 g, 59.4%). 
bH[CDCh, 300 MHz]: 4.17 (s, H-4'), 4.34 (s, H-4') (these two signals integrate 1 H), 
4.48 (1 H, m, H-3'), 5.33 (dd, J = 4.4 and 7.9, H-2'), 5.34 (H-2') (these two signals 
integrate 1 H), 6.20 (d, J =7.8, H-l '),6.21 (d, J = 7.8, H-1') (these two signals integrate 1 
H), 8.19 (s, H-2), 8.21 (s, H-2) (these two signals integrate 1 H), 8.49 (1 H, br, NH), 8.61 
(s, H-8), 8.64 (s, H-8) (these two signals integrate 1 H), 6.74-7.49 (17 H, Ar). 
bp[CDCh, 121.5 MHz]: 148.67 and 150.21 
Rf: 0.42 (hexane-acetone-triethylamine, 50:50:2 v/v) 
2' -0-[1-( 4-Chlorophenyl)-4-ethoxypiperidin-4-yl]-5' -0-(4,4' -dimethoxytrityl)-
6-N-pivaloyladenosine-3' -(2-0-cyanoethyl) N, N-diethylphosphoramidUe 88b 
2' -0-[1-( 4-Chlorophenyl)-4-ethoxypiperidin-4-yl]-5' -0-(4,4' -dimethoxytrityl)-6-N-
pivaloyladenosine 87b (2.00 g, 2.24 mmol) was co-evaporated with dry toluene (2 x 5 m!). 
The residue was redissolved in dry acetonitrile (25 ml) followed by addition of N,N-
diisopropylethylamine (1.6 mI, 8.96 mmol, 4 mol equiv.). After 5 min, 2-0-cyanoethyl-
N,N-diethyl phosphorochloridite (0.93 g, 4.48 mmol, 2 mol equiv.) was added. After 1.5 
h, the solvent was removed under reduced pressure. The residue was purified by column 
chromatography on silica gel. The appropriate fractions, which were eluted with 
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hexane-acetone-triethylamine (65:35:2 v/v) were collected and concentrated under 
reduced pressure to give the title compound as a light yellow glass (1.87 g, 77.4%). 
8H[CDCh, 300 MHz]: 4.33 (H-4'), 4.43 (H-4') (these two signals integrate 1 H), 4.56 (1 
H, m, H-3'), 5.34 (H-2'), 5.42 (dd, J= 5.l and 7.8, H-2') (these two signals integrate 1 
H), 5.86 (d, J = 8.5, H-l '), 6.98 (, J = 8.5, H-l ') (these two signals integrate 1 H), 6.74-
7.64 (22 H, Ar), 7.83 (s, H-8), 7.86 (s, H-8) (these two signals integrate I H). 
8p[CDCh, 121.5 MHz]: 149.32 and 150.64 
Rf: 0.41 (hexane-acetone-triethylamine, 65:35:2 v/v) 
2' -0-[1-( 4-Chlorophenyl)-4-ethoxypiperidin-4-yl]-5' -0-(4,4' -dimethoxytrityl)-
uridine-3' -(2-0-cyanoethyl) N, N-diethylphosphoramidite SSa 
o 
I NH 
2' -0-[1-( 4-Chlorophenyl)-4-ethoxypiperidin-4-yl]-5' -0-(4,4' -dimethoxytrityl)uridine 
SSa (1.00 g, 1.28 mmol) was co-evaporated with dry toluene (2x5 ml). The residue was 
redissolved in dry acetonitrile (15 ml) followed by addition of N,N-
diisopropylethylamine (1.1 mI, 6.38 mmol, 5 mol equiv.). After 5 min, 2-0-cyanoethyl-
N,N-diethyl phosphorochloridite (0.53 g, 2.55 mmol, 2 mol equiv.) was added. After 1.5 
h, the solvent was removed under reduced pressure. The residue was purified by column 
chromatography on silica gel. The appropriate fractions, which were eluted with 
hexane-acetone-triethylamine (65:35:2 v/v) were collected and concentrated under 
reduced pressure to give the title compound as a light yellow glass (0.89 g, 71.8%). 
99 
8H[CDCh, 300 MHz]: 4.16 (s, H-4') (these two signals integrate 1 H), 4.29 (s, H-4') 
(these two signals integrate 1 H), 4.46 (1 H, m, H-3'), 4.67 (dd, J = 4.8 and 7.6, H-2'), 
4.85 (dd, J = 4.8 and 7.9, H-2') (these two signals integrate 1 H), 5.30 (1 H, d, J =8.0, H-
I'), 6.24 (1 H, t, J = 8.0, H-5), 6.80-7.40 (17 H, Ar), 7.77 (d, J = 8.1, H-6), 7.80 (d, J = 
8.1, H-6) (these two signals integrate 1 H). 
8p[CDCh, 121.5 MHz]: 149.06 and 150.17 
Rf : 0.41 (hexane-acetone-triethylamine, 65:35:2 v/v) 
N-(6-Hydroxyhexyl)trifluoroacetamide 91 
o 
F3C)lN~OH 
H 
To a solution of 6-hydroxyhexyl-l-amine 90 (1.21 g, 8.53 mInol) in dichloromethane (3 
ml) ethyl trifluoroacetate 89 (0.60 g, 4.27 mInoI, 0.5 mol equiv.) was added. After 2 h, a 
second portion of ethyl trifluoroacetate 89 (0.60 g, 4.27 mmol, 0.5 mol equiv.) was added. 
After another 2 h, the mixture was concentrated under reduced pressure. The residue was 
purified by column chromatography on silica gel. The appropriate fractions, which were 
eluted with dichloromethane-methanol (96:4 v/v) were collected and concentrated under 
reduced pressure to give the title compound as a white solid (1.58 g, 86. 9%). 
FAB-MS found [M+Ht = 214.10578, CgH14F3NO/ requires 214.10549. 
8H[(CD3)2S0, 300 MHz]: 1.27-1.31 (4 H, m, CH2), 1.38-1.43 (2 H, m, CH2), 1.45-l.50 
(2 H, m, CH2), 3.15-3.18 (2 H, m, CH2), 3.36-3.39 (2 H, m, CH2), 4.35 (1 H, s, OH), 9.40 
(1 H, s, NH). 
8c[(CD3)2S0, 75.5 MHz]: 25.5 (CH2), 26.5 (CH2), 26.5 (CH2), 28.7 (CH2), 32.9 (CH2), 
39.5 (CH2), 61.1 (CH2), 113.6-119.3 (CF3), 156.2-156.9 (C=O). 
Rf : 0.47 (dichloromethane-methanol, 95:5 v/v) 
100 
(6-Trifluoroaeetamido )hexyl-(2-0-cyanoethyl) N,N-diisopropylphospboramidite 92 
o 
F CAN~O'p/O~CN 
3 H I 
,Ny 
N-(6-Hydroxyhexyl)trifluoroacetamide 91 (0.50 g, 2.35 mmol) was co-evaporated with 
dry toluene (2x2 ml) and then dissolved in dry dichloromethane (8 ml) followed by 
addition of N,N-diisopropylethylamine (1.6 mI, 9.39 mmol, 4 mol equiv.). After 5 min, 
2-0-cyanoethyl-N,N-diisopropyl phosphorochloridite (1.11 g, 4.69 mmol, 2 mol equiv.) 
was added. After 15 min, the solvent was removed under reduced pressure and the 
residue was purified by column chromatography on silica gel. The appropriate fractions, 
which were eluted with hexane-acetone-triethylamine (80:20:2 v/v) were collected and 
concentrated under reduced pressure to give the title compound as a colorless oil (0.56 g, 
57.7%). 
* op[D20, 121.5 MHz] : 147.28 
Rf : 0.68 (hexane-acetone-triethylamine, 80:20:2 v/v) 
Solid phase synthesis of oligoribonucleotides 
Solid phase synthesis of oligoribonucleotides was performed on an ABI 3400 DNA 
synthesizer. Standard 1.0 ~mol cycle conditions were applied with a coupling time of 2 
min. All phosphoramidite solutions (8Sa, 88b, 88e, 88d, 92) are 70 mM concentration in 
dry acetonitrile. A solution of 5-benzylthio-lH-tetrazole in dry acetonitrile (0.25 M) was 
used as the activator. Solid phase synthesis of U9U and A9A were carried out in "DMTr-
off' mode; solid phase synthesis of C6-amino modifier-U9U was carried out in "DMTr-
on" mode. The average stepwise yield (ASWY), as reported by the synthesizer, was used 
to evaluate the synthesis efficiency. After synthesis was complete, the resins were 
incubated in concentrated aqueous ammonia (28%) at 55°C for 12 h. The supernatant 
• using D20 capillary 
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was subsequently lyophilized to gIVe partially-protected (Cpep protected) 
oligoribonucleotides. 
U9U93 
ESI-MS found M-= 5138.5, C207H254C19N290S7P9- requires 5138.2. 
Rt (CIS): 8.53 min. 
A9A94 
ESI-MS found M-= 5368.7, C2I7H264C19Ns9067P9- requires 5168.6. 
Rt (CIS): 8.90 min. 
C6-amino modifier-UgU 95 
ESI-MS foundM-= 5316.4, C213H268C19N30090PIO-requires 5317.4. 
Rt (CIS): 8.52 min. 
Man-UgU96 
Amino-modified U9U (C6-amino modifier-U9U) 95 (0.75 Ilmol, 1 mol equiv.) was first 
dissolved in methanol (200 Ill), followed by addition of an aqueous solution (70 Ill) of 
squarate-activated monovalent mannoside (3.75 Ilmol, 5 mol equiv.) and triethylamine (3 
Ill). The reaction mixture was incubated at 37°C. After 2 h, additional aqueous solution 
of squarate-activated monovalent mannoside (37 Ill, 2 mol equiv.) was added. After an 
additional period of 3 h, the reaction mixture was lyophilized and was purified by semi-
preparative CIS RP-HPLC column. The appropriate fractions were collected and 
lyophilized to give Man-U9U was obtained as a white solid. 
Rt (C I8): 7.63 min. 
ESI-MS found M- = 5319.4, C22SH283C19N3109SPIO- requires 5618.6. 
Bi-Man-UgU 97 
Amino-modified U9U (0.5 Ilmol) 95 was dissolved in methanol (300 Ill), followed by 
addition of an aqueous solution (73 Ill) of squarate-activated bivalent mannoside (2 Ilmol) 
and triethylamine (5 Ill). The reaction mixture was incubated at 37°C. Additional 
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portions of aqueous solution of squarate-activated bivalent mannoside (37 Ill, 2 mol 
equiv.) were added at 3 and 6 h, respectively. After 9 h, the products were lyophilized to 
give a white solid. The products were purified on a semi-preparative CIS RP-HPLC 
column. The appropriate fractions were collected and lyophilized. The purified Bi-Man-
UgU was characterized by RP-HPLC and ESI-MS. 
Rt (CIS): 7.34 min. 
ESI-MS found M- = 6152.6, C247H322C19N3601OSPlO-, requires 6152.2. 
General procedures for the removal of Cpep 
Substrate (oligoribonucleotides with 2' -Cpep protection, purified previourly by C 18 
column) was dissolved in DMA (300 Ill) followed by addition of triethylammonium 
formate buffer (TEAF, 200 Ill, pH 2.52,0.5 M). The mixture was incubated at 40°C for 6 
h. The reaction mixture was then neutralized by addition of triethylammonium acetate 
buffer (TEAA, pH 10.0). Chloroform (300 Ill) was added, followed by vortex and 
centrifugation. The organic layer was discarded and the aqueous layer was further 
extracted with chloroform (2x300 Ill). The aqueous layer was lyophilized to give a light 
yellow gel. This material was redissolved in water (30 Ill), followed by addition of n-
butanol (500 Ill). After vortexing, the mixture were frozen in liquid nitrogen and 
centrifuged for 10 min. The butanol layer was discarded. The pellet was dissolved in 
water (500 Ill) and lyophilized to give the fully deprotected-conjugate. 
C6-amino modifier-U1o 100 
Rt (DNAPac PAlOO): 3.40 min. 
ESI-MS found M- = 3177.7, C96HI24N210SIPlO-, requires 3177.8. 
Man-UI0 101 
Rt (DNAPac PAlOO): 3.66 min. 
ESI-MS found M- = 3479.1, ClOsH139N220S9PlO-, requires 3479.1. 
Bi-Man-UI0 102 
Rt (DNAPac PAlOO): 2.70 min. 
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ESI-MS found M- = 4012.6, Cl3oHI78N27099PIO- requires 4012.7. 
U1098 
ESI-MS found M-= 2998.4, C90HlION20078P9- requires 2998.7. 
Rt (DNAPac PA100): 2.79 min. 
A10 99 
ESI-MS found M-= 3229.2, ClOoH12oNsoOs8P9- requires 3229.l. 
Rt (DNAPac PA100): 2.95 min 
Enzymatic stability ofUlO, Man-U10, and Bi-Man-U1o 
0.183 ODU of substrate (UIO 98, Man-UIO 101, and Bi-Man-UIO 102) was dissolved in 
200 III of Tris-Cl buffer (pH 8.0). Rnase A (100x dilute of stock solution, 5 Ill) and 
alkaline phosphatase (lOOx dilute of stock solution, 5 Ill) were added. The stock 
solutions of Rnase A were obtained by dissolving Rnase A (0.001 g) in 0.1 M Tris-Cl 
buffer (pH 8.0, 1.0 ml) and bacterial alkaline phosphatase was obtained by dissolving ca. 
2 units of enzyme in 1.0 ml of the same buffer. The mixture was incubated at 37°C. 
Aliquots (20 Ill) were withdrawn at the following time, 0, 2, 5, 10, 15,20,40, and 60 min. 
To the aliquots were added an aqueous solution of aluminon (5 11M, 20 Ill) and the 
mixtures were frozen in liquid nitrogen immediatedly. All aliquots were analyzed with 
anion exchange HPLC (DNAPac PAIOO). 
UV Thermal denaturation studies 
0.15 A260 units of the AIO 99 was mixed with 12 A260 units of each of the 
oligoribonucleotides (UI098, Man-UIO 101, and Bi-Man-UIO 102) and the oligomers were 
dried using a speed-vacuum. The pellet was resuspended in a 90 mM sodium chloride, 10 
mM sodium phosphate, and 1 mM EDTA buffer (pH 7.0) solution. The mixtures were 
heated to 90°C for 10 minutes then allowed to cool to room temperature for 30 minutes 
and finally stored at 4 °C overnight. Denaturation curves were obtained by monitoring 
the OD at 260 nm while the cells were being heated from 10°C to 90°C at a rate of 
104 
O.SoC/minute using a Varian CARY Model 3E spectrophotometer fitted with a 6-sample 
thermostatted cell block and a temperature controller. 
Methyl 2, 3, 5-tri-O-benzyl-D-(-)-riboside 108 
BnO 
OMe 
OBn OBn 
D-(-)-Ribose 106 (3.00 g, 19.98 mmol) was dissolved in a solution of HCl-methanol 
(1 :99 v/v, SO ml). After the reaction mixture was stirred at room temperature for 24 h, 
solid sodium bicarbonate (1.0 g) was added. The procucts were evaporated under reduced 
pressure to ca. 113 of the original volume, and then filtered. The filtrate was concentrated 
under reduced pressure to give methyl riboside as a yellow oil. This material was 
azeotroped with dry toluene (2xlO ml). The residue was dissolved in dry DMF (60 ml) 
and cooled (ice-water bath), followed by addition of sodium hydride (4.00 g, 100 mmol, 
5 mol equiv.). After 20 min, benzyl bromide (17.10 g, 100 mmoI, S mol equiv.) was 
added dropwise at O°C. The reaction mixture was allowed to warm up to room 
temperature and stirred overnight. After the reaction was quenched by addition of 
methanol (10 ml), the solvents were removed under reduced pressure. The residue was 
redissolved in dichloromethane (120 ml) and extracted with saturated sodium hydrogen 
carbonate (100 ml). The aqueous layer was back extracted with dichloromethane (20x2 
ml) and the combined organic layers were dried (MgS04) and evaporated under reduced 
pressure. The residue was purified by column chromatography on silica gel 
I 
(dichloromethane-methanol 99.S:0.5 v/v). Methyl 2,3,5-tri-O-benzyl-D-riboside 108 
(S.32 g, 61.4% over two steps) was obtained as a light yellow oiL 
8H [CDCh, 600 MHz]: 3.S6 (1 H, dd, J = 5.82 and 10.68, H-5'), 3.67 (1 H, dd, J = 3.54 
and 1O.S0, H-5"), 3.89 (l H, d, J = 4.56, H-2'), 4.07 (1 H, t, J = S.52, H-3 '),4.40 (l H, 
m, H-4'), 4.50 (1 H, d, J = 11.82, CH), 4.59 (l H, d, J = 11.22, CH), 4.60 (1 H, d, J = 
I1.S2, CH), 4.63 (1 H, d, J = 12.24, CH), 4.66 (l H, d, J = 12.18, CH), 4.72 (1 H, d, J = 
12.00, CH), 4.97 (1 H, s, H-l '). 
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8c[CDCh, 600 MHz]: 71.4 (CH, C-S'), 72.3 (CH2), 72.S (CH2), 73.2 (CH2), 78.4 (CH, 
C-3'), 79.7 (CH, C-2'), 80.5 (CH, C-4'), 106.4 (CH, C-1 '), 127.6-138.4 (CH and C). 
Rf : 0.58 (dichloromethane-methanol, 98:2 v/v) 
2,3, 5-Tri-O-benzyllactone 110 
BnO 
o 
OBn OBn 
Methyl 2,3,S-tri-O-benzyl-D-riboside 108 (2.00 g) was dissolved in a mixture of dioxane 
and 0.12 M hydrochlorid acid (4: 1 v/v, 75 ml). The solution was heated, under reflux, 
overnight. The products were concentrated and purified by column chromatography on 
silica gel (dichloromethane-methano198:2 v/v). 2,3,5-Tri-O-benzyl-D-ribose 109 (1.62 g, 
83.5%) was obtained as a light yellow oil. 
2,3,5-Tri-O-benzyl-D-ribose 109 (4.87 g, 11.6 mmol) was co-evaporated with dry 
toluene (2xlO ml) and then dissolved in dry DMSO (15.8 mI, 232 mmol, 20 mol equiv.), 
followed by addition of acetic anhydride (10.9 ml, 116 mmol, 10 mol equiv.) at room 
temperature. After 20 h, methanol (15 ml) was added, and the products were 
concentrated under reduced pressure. Upon addition of ice water (100 ml) to the residue, 
a yellow syrup was formed around the flask. The syrus was dissolved in dichloromethane 
(120 ml), and the aqueous layer was back-extracted with dichloromethane (100 ml). The 
combined organic layers were dried (MgS04) and concentrated under reduced pressure. 
The residue was purified by column chromatography on silica gel (hexane-ethyl acetate 
80:20 v/v). The 2,3,5-tri-O-benzyl lactone 110 was obtained as a white solid (3.85 g, 
79.4%). 
FAB-MS found [M+Ht = 419.16902, C26H270 S+ requires 419.18585. 
oH[CDCh, 600 MHz]: 3.58 (1 H, dd, J = 2.64 and 11.04, H-5'), 3.69 (1 H, dd, J = 2.82 
and 11.04, H-5"), 4.13 (1 H, dd, J= 1.89 and 5.67, H-2'), 4.43 (1 H, t, J= 5.88, H-3'), 
4.44 (1 H, d, J = 11.76, CH), 4.52 (1 H, d, J = 11.88, CH), 4.58 (1 H, m, H-4'), 4.57 (1 H, 
106 
d, J = 11.94, CH), 4.73 (1 H, d, J =11.82, CH), 4.77 (1 H, d, J =11.94, CH), 4.97 (1 H, d, 
J=11.94, CH), 7.19-7.41 (15 H, m). 
8c[CDCh, 150.9 MHz]: 68.8 (CH, C-5'), 72.4 (CH, C-4'), 72.8 (CH2), 73.7 (CH2), 73.8 
(CH, C-3'), 75.4 (CH, C-2'), 81.8 (CH2), 127.5-138.6 (CH and C), 173.8 (C=O). 
Rf : 0.54 (hexane-ethyl acetate, 70:30 v/v) 
1-(2,3,5-Tri-O-benzyl-p-D-ribofuranosyl)phenanthrene ll2a 
BnO 
OBn OBn 
9-Bromophenanthrene 113a (0.922 g, 3.59 mmol) was co-evaporated with dry toluene 
(2x5 ml) and dissolved in dry THF (20 ml). The solution was then cooled to -78°C 
(acetone-dry ice bath) followed by addition of n-butyllithium (2.24 mI, 1.6 M solution in 
hexane, 3.58 mmol) over 2 min. After 40 min, a pre-cooled (-78°C) solution of 2,3,5-tri-
O-benzyl lactone 110 (1.00 g, 2.39 mmol) in dry THF (5 ml), which was prepared by 
first co-evaporating 2,3,5-tri-O-benzyl lactone 110 with dry toluene (2x5 ml) followed 
by dissolving in dry THF, was added over 2 min. Stirring was continued for 3 h at the 
same temperature. The reaction mixture was then allowed to warm up to room 
temperature over a period of 2 h. Solid carbon dioxide (1.0 g) followed by saturated 
aqueous sodium hydrogen carbonate (10 ml) were added. The products were 
concentrated under reduced pressure and the residue was taken up in dichloromethane 
(40 ml) and extracted with saturated aqueous sodium hydrogen carbonate (2x20 ml). The 
aqueous layer was back extracted with dichloromethane (10 ml) and the combined 
organic layers were dried (MgS04) and evaporated under reduced pressure. The residue 
was further co-evaporated with dry toluene (2x5 ml), and then dissolved in dry 
dichloromethane (40 ml). After the solution was cooled to -78°C (acetone-dry ice bath), 
triethylsilane (2.3 mI, 14.4 mmol) followed by boron trifluoride diethyl etherate (1.7 mI, 
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13.7 mmol) were added over a period of 5 min. The reaction mixture was stirred at the 
same temperature for 30 min, and was then allowed to warm up to room temperature 
over a period of 3 h. The products were partitioned between dichloromethane (l00 ml) 
and saturated aqueous sodium hydrogen carbonate (100 ml). The aqueous layer was back 
extracted with dichloromethane (2x10 ml) and the combined organic layers were dried 
(MgS04) and evaporated under reduced pressure. The residue was purified by column 
chromatography on silica gel. The appropriate fractions, which were eluted by hexane-
ethyl acetate (90: 1 0 v/v) were combined and evaporated under reduced pressure to give 
the title compound as a pale yellow solid (0.72 g, 51.9%). Colourless needles were 
obtained after re-crystallization from methanol. M.p. 79-80°C. Found, in material 
recrystallized from methanol: C, 82.60; H, 6.26. Calc. for C40H3604: C, 82.76; H, 
6.25. 
EI-MS found M+ = 580.26233, C4oH360 4 requires 580.26136. 
8H [CDCh, 600 MHz]: 3.84 (l H, dd, J = 3.3 and 10.6, H-5'), 4.01 (1 H, dd, J = 2.7 and 
10.6, H-5"), 4.19 (l H, t, J= 4.2, H-2'), 4.24 (l H, dd, J= 4.5 and 6.5, H-3'), 4.53 (1 H, 
ddd, J = 2.7,6.2 and 6.2, H-4'), 4.57 (l H, d, J = 11.6, C!b), 4.58 (1 H, d, J = 11.8, CH2), 
4.65 (1 H, d, J= 11.8, C!b), 4.69 (1 H, d, J= 11.8, C!b), 4.74 (1 H, d, J= 11.8, C!b), 
4.81 (1 H, d, J= 11.6, C!b), 5.83 (l H, d, J= 4.2, H-l'), 7.28-7.67 (20 H, m), 8.10-8.14 
(2 H, m), 8.66 (l H, d, J = 8.3), 8.75 (1 H, d, J = 8.3). 
8dCDCh, 150.9 MHz]: 69.6 (CH, C5'), 72.7 (CH2), 73.2 (CH2), 73.5 (CH2), 78.2 (CH, 
C3'), 80.3 (CH, C4'), 81.7 (CH, Cl '), 82.3 (CH, C2'), 122.3 (CH, Ar), 123.2 (CH, Ar), 
124.2 (CH, Ar), 124.5 (CH, Ar), 126.2 (CH, Ar), 126.5 (CH, Ar), 126.6 (CH, Ar), 126.7 
(CH, Ar), 127.6, 127.7, 127.8, 128.4, 128.5, 129.1 (CH, Ar), 130.1, 130.6, 131.5, 134.2, 
138.0, 138.2, 138.2, 138.4. 
Rf: 0.40 (hexane-acetone, 80:20 v/v) 
108 
9-(2,3,5-Tri-O-benzyl-p-D-ribofuranosyl)pyrene 112b 
OBn OBn 
The title compound was synthesized following the procedure described above for the 
synthesis of 2,3,5-tri-O-benzyl-,B-D-ribofuranosyl phenanthrene 112a. After column 
chromatography on silica gel (hexane-ethyl acetate 93:7 v/v) , the title compound was 
obtained as a pale yellow solid (34.3%). M.p. 104-105°C (material re-crystallized from 
methanol). Found, in material recrystallized from methanol: C, 83.40; H, 6.03. Calc. 
for C42H3604: C, 83.42; H, 6.00. 
EI-MS found M+ = 604.26000, C42H3604 requires 604.26136. 
bH[CDCh, 600 MHz]: 3.82 (1 H, dd, J = 3.6 and 10.4, H-5'), 3.93 (1 H, dd, J = 3.6 and 
10.4, H-5"), 4.18 (1 H, dd, J= 5.2 and 6.2, H-2'), 4.24 (1 H, dd, J= 4.8 and 5.0, H-3'), 
4.45 (1 H, d, J = 11.9, Clh.), 4.56 (1 H, m, H-4'), 4.56 (1 H, d, J = 11.8, Clh.), 4.66 (1 H, 
d, J = 11.9, Clh.), 4.67 (1 H, d, J = 12.1, Clh.), 4.74 (1 H, d, J = 11.9, Clh.), 4.75 (1 H, d, 
J= 12.1, Clh.), 6.l4 (1H, d, J= 6.2, H-l'), 7.13-7.43 (15 H, m), 8.04-8.14 (5 H, m), 8.22 
(2 H, m), 8.33 (1 H, d, J = 8.0),8.49 (1 H, d, J = 9.2). 
8c[CDCh, 150.9 MHz]: 69.6 (CH, C5'), 72.7 (CH2), 73.2 (CH2), 73.5 (CH2), 78.2 (CH, 
C3'), 80.3 (CH, C4'), 81.7 (CH, Cl '), 82.3 (CH, C2'), 122.3 (CH, Ar), 123.8 (CH, Ar), 
124.7, 124.8, 125.0, 125.1, 125.9, 127.2, 127.5, 127.6, 127.7, 127.8,127.9, 128.1, 128.2, 
128.3, 128.4, 128.5, 130.7, 131.4, 133.9, 137.8, 138.0, 138.3. 
Rf : 0.35 (hexane-acetone, 80:20 v/v) 
I-D-Ribofuranosyl phenanthrene 
1-(2,3,5-Tri-O-benzyl-,B-D-ribofuranosyl)phenanthrene 112a (0.550 g, 0.95 mmol) was 
co-evaporated with dry toluene (2x5 ml), and then dissolved in dry dichloromethane (60 
109 
ml). The solution was cooled to -78°C (acetone-dry ice bath), followed by addition of 
boron tribromide (0.1 Min a mixture of hexane and dichloromethane 1:9 v/v, 33.2 mI, 
3.32 mmol) over a period of 30 min. The reaction was allowed to proceed for 2 h at the 
same temperature and was then quenched by addition of aqueous methanol (20 ml, 
methanol-water 4:1, v/v). The mixture was then allowed to warm up to room 
temperature. After 2 h, the products were concentrated under reduced pressure and then 
further co-evaporated with methanol (3 x 10 ml) under reduced pressure. The residue was 
purified by column chromatography on silica gel. The appropriate fractions, which were 
eluted with dichloromethane--methanol (98:2 to 95:5 v/v) were combined and evaporated 
under reduced pressure. The a- and f3-anomers were obtained as light yellow glasses in 
39.0% (0.114 g) and 24.3% (0.071 g) yields, respectively. 
l-a-D-Ribofuranosyl phenanthrene 114b 
HO 
EI-MS found M+ = 310.12077, CI9H1804 requires 310.12051. 
oH[(CD3)2S0, 600 MHz]: 3.58 (1 H, ddd, J = 4.7, 4.9 and 11.8, H-5'), 3.79 (1 H, ddd, J 
= 2.5, 4.9, and 11.8, H-5"), 4.02 (1 H, ddd, J = 2.3, 4.7 and 8.6, H-4'), 4.32 (1 H, ddd, J 
= 4.3,7.9 and 8.7, H-3'), 4.43 (1 H, dd, J= 4.4 and 7.9, H-2'), 4.47 (1 H, d, J= 4.5,2'-
OH), 4.82 (1 H, t,J= 5.7, 5'-OH), 4.89 (1 H, d,J= 7.5, 3'-OH), 5.75 (1 H, d,J= 2.7, H-
I'), 7.61-7.71 (4 H, m), 7.96 and 7.98 (2 H), 8.11 (1 H, d, J = 8.1), 8.81 (1 H, d, J = 7.9), 
8.88 (1 H, d, J = 8.1). 
Oc[(CD3)2S0, 150.9 MHz]: 62.2 (CH, C5'), 73.0 (CH, C2'), 73.2 (CH, C3'), 79.8 (CH, 
Cl '), 82.3 (CH, C4'), 123.1 (CH, Ar), 123.8 (CH, Ar), 124.1 (CH, Ar), 125.3 (CH, Ar), 
126.6 (CH, Ar), 126.8 (CH, Ar), 127.2 (CH, Ar), 127.3 (CH, Ar), 128.9 (CH, Ar), 129.8, 
130.1,130.2, 131.6, 133.6. 
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Rf : 0.57 (dichloromethane-methanol, 90:10 v/v) 
I-f3-D-Ribofuranosyl phenanthrene 114a 
HO 
OH OH 
EI-MS found M+ = 310.12031, CI9HlS04 requires 310.12051. 
oH[(CD3)2S0, 600 MHz]: 3.69 (1 H, ddd, J = 5.2, 5.5 and 11.8, H-5'), 3.83 (1 H, ddd, J 
= 2.8,5.6, and 11.9, H-5"), 3.90 - 3.99 (3 H, m, H-3', H-4' and H-2'), 4.96 (1 H, t, J= 
5.7,5' -OH), 4.97 (1 H, d, J = 6.1, 3' -OH), 5.31 (1 H, d, J = 5.2, 2' -OH), 5.41 (1 H, d, J = 
3.7, H-l'), 7.63-7.74 (4 H, m), 7.96 (1 H, dd, J= 1.2 and 8.1),8.13 (1 H, s), 8.25 (1 H, 
dd, J = 1.2 and 8.1), 8.81 (1 H, d, J = 8.1), 8.89 (1 H, dd, J = 1.2 and 8.1). 
oc[(CD3)2S0, 150.9 MHz]: 61,7 (CH, C5'), 70.8 (CH, C3'), 76.5 (CH, C2'), 82.7 (CH, 
Cl '), 83.5 (CH, C4'), 123.2 (CH, Ar), 123.8 (CH, Ar), 124.0 (CH, Ar), 125.0 (CH, Ar), 
127.0 (CH, Ar), 127.2 (CH, Ar), 127.3 (CH, Ar), 127.4 (CH, Ar), 129.1 (CH, Ar), 129.9, 
130.1, 130.4, 131.5, 135.6. 
Rf: 0.54 (dichloromethane-methanol, 90:10 v/v) 
9-D- ribopyranosyl pyrene 115 
9-(2,3,5-Tri-O-benzyl-fJ-D-ribofuranosyl) pyrene U2b (0.570 g, 0.94 mmol) was 
deprotected following the same procedure as described above for the debenzylation of 1-
(2,3,5-tri-O-benzyl-fJ-D-ribofuranosyl) phenanthrene U2a. After column 
chromatography on silica gel (dichloromethane-methano198:2 to 97:3, v/v), the fJ and a-
anomers (USa and USb) were obtained as a light brown solid (0.041 g, 13.2%) and a 
light yellow glass (0.039 g, 12.3%), respectively. 
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9-a-D- ribopyranosyl pyrene U5b 
OH 
EI-MS found M+ = 334.12096, C21H1804 requires 334.12051. 
oH[(CD3)2S0, 600 MHz): 3.87-3.89 (1 H, hr, m, H-5' and H-4'), 3.96 (l H, hr, m, H-2'), 
4.04 (1 H, ddd, J= 3.0, 3.3 and 6.2, H-3'), 4.15 (1 H, dd, J= 1.7 and 12.2, H-5"), 4.65 (1 
H, d, J= 8.0, 2'-OH), 4.91 (l H, d, J= 6.7, 3'-OH), 5.23 (l H, d, J= 6.1, 4'-OH), 5.54 (l 
H, s, H-l'), 8.07 (1 H, t,J= 7.6),8.17 (2 H, s), 8.22 (l H, d,J= 9.3),8.28-8.31 (4 H, m), 
8.37 (1 H, d, J = 9.3). 
oc[(CD3)2S0, 150.9 MHz]: 69.2 (CH, C3'), 70.0 (CH, C4'), 72.0 (CH, C5'), 73.6 (CH, 
C2'), 77.9 (CH, Cl '), 123.3 (CH, Ar), 124.2, 124.6, 124.8 (CH, Ar), 125.4 (CH, Ar), 
125.6 (CH, Ar), 126.3 (CH, Ar), 126.5 (CH, Ar), 126.7, 127.3 (CH, Ar), 127.7 (CH, Ar), 
127.9 (CH, Ar), 130.2, 130.6, 131.3, 134.5. 
Rf: 0.64 (dichloromethane-methanol, 90:10 v/v) 
9-fJ-D- ribopyranosyl pyrene USa 
HO'" 
\\,-
OH 
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EI-MS found M+ = 334.12007, C21HlS04 requires 334.120Sl. 
8H[(CD3)2S0, 600 MHz]: 3.68-3.71 (1 H, dd, J = 5.4 and 10.2, H-S'), 3.76 (1 H, t, J = 
10.4, H-5"), 3.82-3.86 (2 H, m, H-2' and H-4'), 4.08 (1 H, br, m, H-3'), 4.63 (1 H, d, J 
= 7.3, 2' -OH), 4.81 (1 H, d, J = 6.6, 4' -OH), 4.98 (1 H, d, J = 3.4,3' -OH), S.39 (1 H, d, J 
= 9.6, H-l '), 8.07 (1 H, t, J = 7.6), 8.1S-8.20 (4 H, m), 8.28 - 8.30 (3 H, m), 8.47 (1 H, d, 
J= 9.4). 
8c[(CD3)2S0, lS0.9 MHz]: 66.4 (CH, CS'), 67.9 (CH, C2' or C4'), 72.0 (CH, C3'), 72.8 
(CH, C2' or C4'), 73.7 (CH, C1 '), 124.3, 124.2, 124.7 (CH, Ar), 12S.1 (CH, Ar), 125.3 
(CH, Ar), 125.5 (CH, Ar), 125.8 (CH, Ar), 126.6 (CH, Ar), 127.2 (CH, Ar), 127.6 (CH, 
Ar), 127.9 (CH, Ar), 129.7, 130.S, 130.7, 131.3, 135.2. 
Rf: 0.S7 (dichloromethane-methanol, 90:10 v/v) 
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